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GENERAL INTRODUCTION 
Understanding Muscle Growth Through Basic Research 
Since muscle is essentialiy the end product in meat animal agriculture, one target of basic 
research has been to understand the nature and control of Its growth. For basic research to yield 
meaningful applied knowledge, the mechanisms for muscle growth must be understood at the 
whole-animal, tissue, cellular, subcellular, and genetic levels. Thus, the experimental approach to 
understanding muscle growth is multifaceted. Several key issues are important: 1) understanding 
the control and regulation of the growth process; 2) developing appropriate methodologies to 
measure observed changes that occur in muscle growth and in the metabolic pathways that drive 
growth; and 3) understanding and interpreting observed measurements in context of the 
experimental setting and conditions. 
In the area of control and regulation of growth, growth stimulants have been one of the 
tools used to understand the metabolic process. The underlying idea in this approach is that by 
enhancing muscle growth through an exogenous agent, the underlying mechanism of normal 
muscle growth and metabolism might be more clearly understood. For example, naturally produced 
hormones in the body such as estrogen, testosterone, and growth hormone have been applied 
exogenously to animals to produce a growth effect. This suggests that these hormones may play 
an important role in regulating normal muscle growth. Future application of these regulators in a 
controlled setting along with measurement of the corresponding changes in metabolic pathways 
may be an effective means of describing their role In regulating normal muscle growth. Similarly, 
an exogenous growth stimulant (pharmaceutical rather than natural) might be applied to produce 
an obvious increase in muscle growth. By measuring the effects of this agent on normal metabolic 
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processes, key regulatory points might be identified and quantitated. Such control points may 
include natural hormone levels, nutrient energy availability, amino acid supply and composition, and 
age related changes in gene expression. Thus, metabolic regulators may be very useful as tools 
in describing normal muscle growth and the processes which contribute to the accumulation of 
muscle protein. 
A second key area to understanding the muscular growth process is the development of 
methodologies to quantify changes in the underlying metabolic pathways. Two of the fundamental 
pathways which affect muscle growth are protein synthesis and protein breakdown. The underlying 
assumption is that muscle growth or atrophy results from changing the relative rates of these two 
opposing metabolic processes. When protein synthesis exceeds protein breakdown, muscles 
accumulate protein and gain mass. When the rate of protein breakdown exceeds the rate of 
synthesis, muscle atrophy occurs. Since these processes are an integral part of muscle growth and 
protein accretion, development of accurate methodologies to measure the rates of protein synthesis 
and protein breakdown in individual tissues will be fundamental to understanding the muscle growth 
process and its regulation. 
Several techniques have been used to study growth at the whole-animal and tissue levels 
such as nitrogen balance, plasma amino acid flux, and tissue protein synthesis. One problem with 
these methodologies is that they are often used independently and rarely conskJered in 
combination. As a result, interpretation of results has been ambiguous. For example, in applying 
P -agonists to animals, one technique such as plasma amino acW flux may suggest that growth was 
enhanced by an increase in protein synthesis (indirectly) while another technique such as 
radioisotope incorporation into mixed muscle proteins may suggest that a decrease in protein 
breakdown was responsible because protein synthesis was the same among treated animal and 
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controls. Thus, it is difficult to determine which metabolic process, protein synthesis or protein 
breakdown, was primarily affected by P -agonists and thereby influenced growth. Since much of 
the previous work in this area has used only a single technique, it is difficult to evaluate whether 
differing results arise from differences between studies or differences between methods. Thus, it 
may be useful to compare these techniques under Identical conditions to assess the appropriate 
use of each technique In describing muscle tissue growth. Knowing the strengths and limitations 
of each method could, in turn, provide direction for further research in choosing the appropriate 
method under given conditions as weil as suggesting possible interpretation of ambiguous results. 
Another methodological consideration in the study of muscle growth Is the development 
of new techniques to measure the rate of proteolysis in vivo. To date, a valid technique to measure 
protein breakdown has not been reported. Most of the literature that refers to changes in protein 
breakdown being responsible for an increase in growth have only Indirectly estimated the rate for 
breakdown. Protein synthesis can be measured with isotopic tracers and growth rate can be 
estimated by change in live weight. Thus, the rate of protein breakdown Is estimated indirectly as 
the difference between synthesis and growth. Hence, it appears that new technology applied to 
accurately measuring the rate of protein breakdown in muscle would greatly impact the study of 
muscle growth and its regulation. 
Given that the appropriate growth regulators and methodologies are available, the 
importance of experimental context must also be considered. This is especially important in making 
the transition between isolated muscle cell culture systems and muscle in the context of the whole 
animal. Tissue culture methods have been developed in order to study specific events In Indivklual 
tissues without the influence of other organs and metabolites. This approach has the advantage 
of reducing the apparent complexity of whole-animal events resulting from interaction between 
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multiple organs and cell types to single events in a specific cell type. In addition, these tissue 
culture studies are relatively Inexpensive relative to whole animal experiments. Thus, muscle tissue 
culture has been a valuable tool in studying the processes and regulation of muscle growth. 
The context of these techniques is crucial, however, because while such experiments reveal 
a great deal about the specific events in muscle tissue, and serve as a great screening tool for 
potential modulators of protein turnover, the data do not necessarily guarantee the relevance to 
the whole animal. For example, an agent might be developed to decrease protein breakdown by 
50% in muscle cell culture, but have no effects in the whole animal system. Similar arguments can 
be made relative to measurement of mRNA levels, enzyme activity and concentration, gene 
expression, and developmental changes in endocrine profiles. The measurement of such 
parameters may be important in characterizing an isolated system, but do not necessarily indicate 
if this system is important in the whole-animal setting. Thus, in light of the complexity of the whole 
animal system, it appears that context is key to determining which events and processes have large 
influences on muscle growth, and which events have only minor importance. 
The Wea of experimental context is also Illustrated in terms of nutritional status. Some 
exogenously applied growth stimulants may only be effective if the animal is compromised 
nutritionally or is In a state of stress, injury, or disease. Other regulators, however, may only be 
effective if nutrients are in excess and conditions are optimal for muscle grov/th. 
On the whole, then, the experimental approach toward understanding the nature and 
control of muscle growth depends greatly on the ability to modify muscle growth in a predictive 
fashion with exogenous growth enhancers, the availability of appropriate methodology to measure 
observed changes In the metabolic changes which support growth, and the interpretation of results 
in terms of the experimental conditions employed. 
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Goals of the Present Study 
The present investigation compared many of the current technologies used to describe 
muscle growth and metabolism. Selected growth enhancers were used as tools to modify muscle 
growth in a predicted fashion. The resulting changes in muscle growth were then assessed by a 
variety of methods and in a variety of tissues in order to characterize the overall Importance of 
protein synthesis and protein breakdown in regulating muscle growth. 
The specific goals were to: 
1. Describe the mechanism of action of p -agonists in stimulating muscle growth. 
2. Evaluate the appropriate use of currently used tracer techniques to describe 
changes in muscle protein accretion. 
The idea behind the first goal was to use specific exogenous agents to modify growth in 
order to determine what factors may control muscle growth in normal conditions. Conclusions 
drawn from this whole-animal and tissue level study should enable scientists to ask appropriate 
meaningful questions about regulation at the cellular and subcellular levels. For example, If p -
agonists primarily act by increasing protein synthesis in tissues, it may be appropriate to invest 
resources to probe specific tissues for specific proteins which are synthesized at a faster rate 
(myofibrillar proteins, sarcoplasmic proteins, etc.). On the other hand, if a decrease in protein 
breakdown is the main effect, probing for specific proteolytic enzyme levels and activity may be 
meaningful. 
It may also be possible that the main effect of P -agonist on muscle growth is mediated 
through another organ such as liver. To speculate, the endocrine pathway of p -agonists may target 
the liver through specific receptors. This would signal the liver to decrease protein synthesis such 
that more amino acids are made available to muscle for protein synthesis. In this scenario, the 
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underlying mechanism for p -agonist stimulation of muscle growth would be metabolic in nature 
rather than through the classical endocrine pathway. The non-comparative approach (focussing on 
one tissue, cell-type, or pathway) would overlook such an effect. Thus, the present strategy may 
identify potential interorgan factors as well as intraorgan factors which may control muscle growth. 
The second goal was concerned with comparing a variety of methods under the same 
experimental conditions in order to assess the ability of each method to detect changes In muscle 
growth which may exist. Ideally, this multiple method approach should provide a better 
understanding of the potential advantages and limitations of each technique. It may also be 
possible that using many methods together would yield more information than using any single 
technique alone. Thus, a combination of methods might be used to better assess nutritional and 
developmental changes in muscle growth in the whole animal which were previously not possible 
to study using single techniques alone. 
Explanation of Dissertation Format 
This dissertation is organized in the alternate format as described in the Iowa State 
University Graduate College Thesis Manual. This allows for the preparation on independent sections 
which are suitable for publication in refereed journals. The literature review describes what is known 
about p -agonist stimulation of muscle growth as well as the assumptions and approach of each 
of the methodologies compared and evaluated. Two individual scientific papers have been prepared 
which are closely related to the theme of muscle growth and protein turnover. The first eluckJates 
possible mechanisms of action of p -agonists on muscle growth. The second discusses potential 
differences resulting from using different techniques to measure tissue protein synthesis and 
potential basis for evaluating these techniques. It also is an attempt to combine the various 
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methodologies to assess which methods best describe muscle protein deposition. Papers and 
relevant discussion are in the format used by the American Journal of Physiology. 
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REVIEW OF THE LITERATURE 
P -Agonist Influence on Protein Metabolism 
Historical background 
Possibly the first study to demonstrate an anabolic effect of adrenergic agonists was 
reported in 1963 (13). Chronic administration of epinephrine (a /P -agonist) in pigs resulted in a 23% 
increase in nitrogen retention, a 10-20% increase in body weight gain, and a 10-20% decrease in 
carcass fat. Later, the anabolic effects of p -agonists on protein metabolism were described by 
studying the adrenergic activation of thermogenesis in rats (50). For example, Emery et al.(15) 
observed that chronic administration of clenbuterol to rats increased both energy intake (23%) and 
expenditure (26%) without changing gross or net energy efficiency. These changes were 
accompanied by a 27% increase in weight gain. Protein and water accounted for the weight gain 
increase because the percentage of carcass fat decreased substantially. Moreover, these effects 
appeared to be limited to p ^-selective agonists because in other studies noradrenaline (a/P), 
prenaiteroi (P ^), and isoprenaline showed no significant changes in gain or carcass composition 
(50). A group at American Cyanamid was the first to describe the influence of orally administered 
P 2-agonists cimaterol and clenbuterol on muscle and fat deposition in livestock species. 
P -agonists effects on growth, feed efficiency and carcass composition 
Several excellent reviews have been published on p-agonist effects on growth and 
metabolism (22,32,50,54). Hanrahan et al. (22) summarized the overall response to cimaterol in 
several species. Sheep exhibited a 13% increase in growth rate and feed efficiency, a 27% 
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decrease in carcass fat, and a 17% increase in longissimus dorsi area. Cattle displayed an increase 
in growth rate and feed efficiency of 17% and 20%, respectively, a 38% decrease in carcass fat, and 
a 42% increase in longissimus dorsi area. Pigs showed a marginal 1-3% increase in growth and 
feed efficiency, and 18% decrease in fat, and a 13% increase in longissimus dorsi area. 
Dose response relationships 
Dose response studies in sheep have ranged from 0.02 to 3.80 mg/kg live weight (6,22). 
Maximal responses were achieved with a dose of up to 0.125 mg/kg live weight. Correspondingly, 
Williams (54) noted responses in sheep with clenbuterol up to 2.0 ppm and cimaterol up to 10 ppm 
in the diet. Less information is available in cattle (22,42). Williams (54) noted an optimum dose 
using 5.0 ppm in the diet. High levels of clenbuterol (1.3 mg/kg live weight), however, were 
associated with decreased feed intake (22). A decrease in feed intake was especially pronounced 
in pigs (22,28,35) with levels greater than 0.03 mg/kg live weight (approximately 1.0 ppm in the 
diet). Lambs, however, do not exhibit a reduction in feed intake when fed up to 0.4 mg/kg live 
weight daily (22). An optimal dose in poultry was 0.025 to 0.5 mg/kg live weight (0.25 to 0.5 ppm 
in the diet) (14,22). Minor and variable effects on gain are likely due to a combination of increased 
protein accretion and decreased fat accretion. Regardless of performance, however, the overall 
efficiency of producing lean meat or carcass muscle mass was improved by feeding p -agonists. 
These results have stimulated further interest in studying their effects on protein metabolism. 
Effects on nitrogen balance 
P -agonists rapidly alter nitrogen metabolism. Clenbuterol treated sheep exhibited a 40% 
increase in nitrogen retention within 24 hours (54) which continued throughout the 7-day treatment 
period studied. A simiiar effect was observed in cimaterol-treated iambs (8). Nitrogen retention 
increased 27% in the first 24 hours of treatment. This was accompanied by a 37% increase in 
piasma giucose concentration, a transient increase in insulin and fatty acid concentrations, and a 
27% decrease in plasma urea in the first 6-10 hours of treatment. These p -agonist-induced changes 
on nitrogen retention quickly returned to control values following withdrawal (8). This nitrogen 
metabolism response was further supported by MacRae et al. (31). They observed a rapid increase 
in nitrogen retention in lambs following treatment with clenbuterol which returned to normal 
following withdrawal. Thus, it appears that p-agonists almost immediately increase nitrogen 
retention suggesting a direct effect on protein metabolism. 
p -agonist action appears to be muscie specific 
The action of p -agonists on protein metabolism appears to be confined to skeletal muscle 
as clenbuterol had no positive effect on the growth of liver, gastrointestinal tract, and kidney in rats 
(41). This was supported by work in cattle (54,55). Moreover, further studies in lambs suggested 
that the increase in skeletal muscle protein was due to an increase in fiber hypertrophy rather than 
hyperplasia (7,29,54). For example, a 30-35% increase In the protein and RNA content In the 
semitendinosus muscles of cimaterol-fed lambs has t)een reported (7). DNA concentration In the 
same muscles, however, was 22% less. Thus, cimaterol-induced hypertrophy caused a rapid 
increase in muscle RNA and protein without additional incorporation of satellite cell nuclei. 
Fiber type controversy 
Muscle fiber size apparently was increased in lambs fed P -agonist, yet reports disagree as 
to whether hypertrophy was limited to a particular fiber type. One study (7) reported a 30% 
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increase in the mean cross-sectionai area of type I (red) and type il (white) fibers in semitendlnosus 
muscles from cimaterol-fed lambs. Type I and type II fiber areas were increased 13% in 
longisslmus muscles. Another study (29), however, observed no difference in the cross-sectional 
area of type I fibers from semitendinosus and longissimus muscles from cimaterol-fed lambs. Type 
II fiber area was 50% greater in both muscles. Therefore, they concluded that the increase in 
muscle mass was due to hypertrophy of type II fibers only. Similar selective increases in type II 
fibers were also observed in cattle (33) and lambs (21). 
The mechanism controversy: evidence for increased protein synthesis 
Controversy also exists in defining the mechanism by which increased protein accretion 
occurs. Some authors maintain that p -agonists act by increasing protein synthesis (15) while others 
assert that the main effect is decreased protein degradation (10,41). An increase in the fractional 
rate of protein synthesis (FSR) has been observed in rats (15). FSR was increased 34% and 26% 
in animals given large doses of clenbuterol and fenoterol, respectively. In contrast, other reports 
have shown that clenbuterol did not increase in FSR or in protein synthesis per unit RNA in rats 
(41). In fact, at later time periods (21-25 days), both estimates of protein synthesis were 
significantly lower in treated animals. The dose of clenbuterol, however, was 10-fold lower, and 
given orally rather than by subcutaneous injection. Yet another study in lambs support showed a 
transient effect on protein synthesis (31). Plasma leucine turnover and oxidation rates in lambs 
were measured at intervals up to 20 days of treatment with clenbuterol. The amount of leucine flux 
available for protein synthesis was estimated as the difference between total flux and oxidation. 
Protein synthesis showed a transient effect as it was initially unaltered at day 4, significantly 
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increased at day 11, and then declined again to control levels by day 18. Thus, the authors 
suggested that the major long-term effect of P -agonists is a depression in protein degradation. 
Evidence for decreased protein breal<down 
Evidence for p -agonists affecting protein breakdown are largely inferred by presuming 
proteolysis is altered because FSR was unchanged. In rats, protein degradation was estimated as 
the difference between FSR and the fractional rate of protein deposition (41). It appeared that 
clenbuterol initially induced a dramatic reduction in the rate of muscle protein degradation in both 
gastrocnemius and soleus muscles, but the effect was diminished over time. The hypothesis that 
P -agonists primarily act by decreasing protein degradation is further supported by work in lambs 
(10,31). For example, Bohorov et al. (10) observed that after a 37-day treatment period, clenbuterol-
fed lambs had a 33% greater rate of protein gain in both the longissimus dorsi and vastus lateralis 
muscles but not the vastus intermedius muscle. No significant differences were observed between 
control and treated lambs, however, in tyrosine flux through the plasma compartment or in the FSR 
measured in these muscles. Thus, the authors concluded that clenbuterol must have increased 
muscle growth by depressing protein degradation. 
Decreased proteinase levels 
Further evidence for p -agonist reduction of protein breakdown comes from measurement 
of proteinase levels in lambs (27,52). Higgins et al. (27) measured the activity of calpain I (umolar 
calcium-activated neutral protease), calpain II (mmolar calcium-activated neutral protease), and the 
endogenous calpain inhibitor calpstatin In longissimus dorsI muscles from lambs. A six-week 
treatment period with clenbuterol (2ppm In the diet) doubled the amounts of calpain II and 
calpstatin. The amount of calpain I was significantly lower, as was calpain I activity. Calpain II 
activity remained unchanged in relation to the amount of inhibitor present. Other authors (52) have 
reported similar overall effects in lambs fed cimaterol (10 ppm In the diet). Calpain I activity was 
reduced in longissimus dorsi muscle by 55% and 70% after 3 and 6 weeks of treatment, 
respectively. Total calpain activity, however, was unaltered by cimaterol treatment. In contrast to 
Higgins et al. (27), however, the amount of calpain I isolated from this muscle was not changed 
(52). Overall the P -agonists appear to increase the rate of protein accretion in muscle primarily 
by decreasing the rate of protein degradation. This may be associated with decreased activity of 
important proteolytic enzymes in the muscle tissue. Other evidence for a decrease in protein 
breakdown is largely indirect. Protein breakdown is thought to be effected because no sustained 
effects on protein synthesis have been observed. 
Signal pathway 
It is unknown whether p-agonists act directly by interaction with the Pj receptor or 
indirectly by release of other hormones. In rats, plasma levels of insulin, growth hormone, and T3 
were unaffected by clenbuterol (15). Insulin levels, however, were significantly reduced by fenoterol 
treatment. In lambs, a 55% and 34% decrease in insulin and IQF-I concentrations have been 
observed, respectively (7). Growth hormone concentration and area under the curve were 2.3 times 
greater in lambs fed cimaterol. Cortisol, prolactin, and glucose concentrations were unaffected. 
Thus, the role of the endogenous endocrine system in mediating the p -agonist response remains 
to be clarified. 
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Structural variants of p -agonists 
Although cimaterol and clenbuterol have been most widely studied, several structural 
variants of p-agonists have been synthesized. One such agonist developed by Lilly Research 
Laboratories, Ractopamine, is currently being tested in domestic livestock species for its effects on 
growth, protein accretion, and fat reduction. Published reports focus on ractopamine effects in 
swine (4,9,39,49). Very little information is available In ruminants. One report, though, indicated that 
steers (287 kg) fed ractopamine (100 ppm in the diet) for 21 days displayed a 51% increase in 
nitrogen retention over control steers .(3) A second trial suggested a linear response in percent 
protein in the 9-10-11 rib section of steers fed ractopamine at 0, 10, 20, 40, 60, or 80 ppm. The 
response was significant at doses greater than 40 ppm. No protein X treatment interaction was 
observed using diets with 11 or 14% crude protein. 
Studies in finishing pigs suggested that the protein content of the diet was, however, 
important to the ractopamine response. For example, Anderson et al. (4) showed that ractopamine 
in the diet (20 ppm) caused a 14.6% Increase in nitrogen retention at 16% dietary crude protein. 
But, a 12% decrease in nitrogen retention was observed at 12% dietary crude protein. This was 
supported in a second dose-response experiment. Here, ractopamine was more effective In 
improving growth performance and carcass composition as dietary crude protein increased from 
12% to 18% (4). 
Relatively little information is available relative to the effects of ractopamine on protein 
metabolism. Adeola et al. (2) demonstrated an increase In the fractional rate of myofibrillar but not 
sarcoplasmic proteins in longisslmus dorsi and biceps femoris muscles of pigs fed ractopamine 
(20 ppm). No differences were noted, however. In the overall fractional synthesis, accretion, or 
breakdown rates of protein In longissimus dorsI, biceps femoris, or gastrocnemius muscles of these 
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pigs. A similar study aiso failed to show ractopamine effects on protein synthesis or degradation 
in an in vitro assay (9). Therefore, in comparison to clenbuterol and cimaterol, the doses of 
ractopamine required were quite high to achieve even minimal effects in increased protein accretion 
and decreased fat deposition in cattle and swine. 
Another structurally modified p-agonist 1-644969 has been developed. Few puldished 
reports are available which document its activity in growing animals. Potentially, L-644969 could 
be used to increase muscle protein accretion at lower optimal doses that clenbuterol, cimaterol, and 
ractopamine without some of the side effects. 
Indirect Methodology to Measure 
Protein Synthesis and Breakdown in the Whole Body and Selected Tissues 
Model of whole-body amino acid metabolism 
Many methods have been used to measure protein turnover In vivo (12,16-19,36,40). The 
simple working model developed by Garlick et al. (17-19) has been used extensively (Figure 1). In 
this conceptual model, normal inputs into the free amino acid pool are from dietary amino adds (I) 
and body protein breakdown (B). Normal outputs from the free amino acid pool are to protein 
synthesis (S) or oxidation (E) which gives rise to end products CO^ and urinary N. Whole body 
protein in this model is a single large pool Interacting with the free amino acid pool by incorporating 
amino acids from plasma into tissue protein (S) while also contributing to the plasma amino ackJ 
pool by degrading tissue proteins (B). In an amino acid tracer experiment, label can be given 
intravenously or orally. After it enters the free amino acM pool (metabolic pool), it can be used for 
protein synthesis (S) or be oxidized (E). It Is assumed that the body protein pool, because of Its 
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(I) DIETARY AMINO ACIDS 
FREE 
AMINO ACID 
POOL 
SYNTHESIS (S) 
BREAKDOWN (B) 
(E) OXIDATION 
1  
N-EXCRETION CO. 
BODY 
PROTEIN 
Figure 1. Simple model for whole-body protein metabolism 
large size, does not "recycle" tracer back to the free amino acid pool during the course of the 
experiment. Thus, when the free amino acid pool Is of constant size, its turnover rate (flux, Q) can 
be described by the following expression 
Q = S + E = B + I Equation 1 
The rates of protein synthesis and breakdown have involved measurement of (Q) by precursor (or 
plasma) methods or by end-product methods depending on the label given. The present review 
will focus only on precursor methods. 
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Measurement of flux by constant Infusion 
Ttie constant infusion metiiod commonly uses a non-nitrogen labelled amino acid such as 
leucine ^H, or ^H^). The label is infused intravenously until specific activity (isotopic 
enrichment) reaches a constant value Typically, a priming dose is given such that plateau 
is reached more rapidly. Flux is then calculated a one-pool flux model by the expression 
0 = Equation 2 
where (i) is the infusion rate. Thus, protein synthesis and breakdown can be calculated, given the 
knowledge of dietary intake from Equation 1. 
Fol (Synthesis) 
Flk (leu—^KIC) 
Fok (Oxidation) 
Flo (Proteolysis) 
Fkl (KIC-*>ieu) 
Fko (entry of KIC) 
Figure 2. Kinetic model describing leucine (LEU) and a -ketolsocaproate (KIC) metabolism in 
vivo 
A two-pool adaptation of the methodology may offer improvements over the classical one-
pool model. A simple working model for this method in lambs and pigs is described by Heiland 
et al.(25) and shown in Figure 2. This method is based on the simultaneous equations of Shipley 
and Clark (46) previously adapted for leucine metabolism (24,38,51). The radioactive tracer model 
can also be adapted for use with stable isotopes by estimating enrichment rather than specific 
activity of respective pools. In this model, (F) is the transfer of unlabelled material from pool to 
pool. Subscripts represent the following: (I), leucine pool; (k), KIC pool; (o), outside the two-pool 
system. (Fko), the transfer rate of entry of KIC can be eliminated when enrichment of leucine and 
KIC obtained during the infusion of labelled leucine are equal. Values for synthesis, proteolysis, 
leu-KIC, KIC-leu, and oxidation can be derived by solving simultaneous equations describing all 
possible rates of entry and exits from the system (25). In general, the two-pool model for leucine 
may yield the most information for the accurate assessment of leucine metabolism and overall 
whole-body protein turnover because the model can estimate the amount of leucine diverted to 
protein synthesis and oxidation pathways without requiring the tedious collection of COg. However, 
the problems with estimating in vivo specific activity at the site of metabolism has raised questions 
as to the validity of this method. In some cases, the model estimates of oxidation may conflict with 
oxidation rates as estimated by classical '^^ CO^ collection (43) 
Method assumptions 
Some basic assumptions accompany the use of precursor methods which have been 
addressed by Garlick and Clugston (18). 
Assumptions are: 
1. The size of the precursor pool remains constant during the period of study. 
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2. Plasma specific activity (enrichment) of the free amino acid reflects specific activity 
(enrichment) at the site of protein synthesis (le. of aminoacyl tRNA). 
3. No isotope effects exist; tracer and tracee amino acids are treated equally. 
4. Amino acid tracers do not themselves affect protein turnover. 
5. Compartmentalization of amino acids does not occur. 
6. Effects of tracer recycling through protein are minimal. 
7. Isotope equilibrates such that enrichment is the same at all sites of protein and 
end-product synthesis. 
The assumption that the size of the precursor pool remains constant during the period of 
study is a necessary requirement for the flux Equation 2 to be true. This is a reasonable 
assumption if the subjects have been in a steady state for some time before measurement. 
The second assumption for specific activity at the site of protein synthesis may not hold true 
because It has been established that the specific activity of free leucine in the tissues (intracellular) 
is lower than plasma. This problem may be complicated by the fact that the free amino acid pool 
may be compartmentalized. Plasma may in practice be a good estimate of precursor specific 
activity as some reports show that tRNA may be charged from the extracellular pool (26,53). On 
the whole, it is difficult to assess the best estimate of specific activity for protein synthesis (tissue 
or plasma). The definitive measure would be to determine the specific activity of the aminoacyl 
tRNA. 
The third assumption Is that no isotope effects are present: tracer and tracee are 
treated equally. For example, under this assumption, tracer in plasma would not be selectively used 
for protein synthesis in favor over tracee amino acid coming from protein breakdown. This would 
result in an overestimate of the rate of protein synthesis. 
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The assumption that the tracers do not themseives affect protein turnover may be iess of 
a probiem with constant infusion because piasma concentrations do not greatly change, in 
contrast, bolus injections of stable isotopes and/or flooding doses can greatly increase plasma 
concentration and the potential for amino acid interactions with protein metabolism (20,48). 
The fifth assumption of no compartmentalization of amino acids means that dietary amino 
acids are treated the same as amino acids derived from protein breakdown. Under this assumption, 
for example, amino acids from protein degradation have an equal chance of being used for protein 
synthesis as amino acids present in plasma [le. plasma specific activity (SA) = intracellular SA = 
aminoacyl tRNA SA]. 
The sixth assumption that the effects of tracer "recycling" through protein are minimal may 
be valid in short-term experiments using constant infusion. But, as longer infusion periods are used, 
the amount of tracer which both enters the body protein pool by synthesis and returns to the free 
amino acid pool by degradation increases (1,45). 
The last assumption is that both models assume that isotope equilibrates such that 
enrichment is the same at all sites of protein and end-product synthesis. This assumption may be 
invalid because of varying degrees of recycling within different tissues and possible slow 
equilibration among body pools. 
Overall, valuable comparative information about the effects of hormonal modulation, 
nutrition, stress and disease can be gained by using isotopes to model protein turnover even 
though absolute quantitation of flux, synthesis, degradation and oxidation may vary between 
models. Knowledge of the limitations and assumptions of each model will also aid in interpreting 
apparently conflicting results. 
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Direct Methods to Measure Protein Synthesis and Breakdown in Individual Tissues 
Constant infusion and large dose flooding techniques for protein synthesis 
Two approaches to measuring the rate of protein synthesis in individual tissues have 
commonly been used: large dose flooding and constant infusion as reviewed previously (17,44). 
The large dose technique was developed to eliminate the need to measure amino acid specific 
activity in the tissue. In this approach, a very large dose of tracer amino acid with known specific 
activity is given to an animal. Specific activity of that tracer in tissues rises very rapidly to a value 
which approaches the specific activity in plasma. The fractional rate of synthesis (K^) of tissue 
proteins can then be calculated over a very short time frame (t) by the equation 
Sfa/Sj = Kg t Equation 3 
where (S^) is the specific activity of protein bound amino acid and S| is the mean plasma 
specific activity over the short time period used. The fall in free amino acid specific activity is linear 
over the first 10 minutes after injection and is therefore easy to measure. 
The advantages of the large dose technique include minimal recycling of tracer from protein, 
an improved estimate of intracellular specific activity, simplicity in calculations, and convenient 
laboratory procedures. 
Several problems exist with this method, however. First, the rate of protein synthesis may 
be altered by using such large, unphysiological doses of tracer amino acid. In addition, more 
animals are required for this technique than for constant infusion (17). The flooding dose method 
to measure protein synthesis could be particularly useful in small laboratory animals in which 
constant infusion is difficult and large numbers of animals can be used. Still, the method has been 
used in sheep to estimate the fractional rate of synthesis in muscle, liver, skin, and whole-body (5). 
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The constant infusion method offers advantages in large animal species. The main 
advantage may be the ability to simultaneously measure amino acid flux, protein synthesis, 
breakdown, and oxidation indirectly as well as estimate protein synthesis directly from tissue biopsy 
in the same study. The mathematical approach, however, is more involved than in the flooding 
dose model described above. The approach was described by Garlick et al. (17) as well as Everett 
and Zak (16). In short, the fractional turnover rate (Kg) in the steady state can be described by; 
dP/dt = Kg(F - P) Equation 4 
where F is the precursor specific activity, P is the protein bound specific activity, and t is time. With 
constant infusion of tracer, F closely approximates a time course whose rate constant (K,) can be 
predicted by the following: 
F = F^g^ [1 - e '^N Equation 5 
FfT^ax is the precursor specific activity at plateau. Integration of equation 4 with the expression of 
the time course of F in equation 5 gives the equation: 
P_ K,  ^d-e"*^* )  Ks 
KrKs*  (i-e"* '^)' ^ rKs ® 
In the liver, K, can be taken to equal which is the measured rate constant for rise to plateau in 
plasma (17). In muscle, the appropriate value for K, is RK^ where R Is the ratio of protein bound 
to free amino acid in the tissue (17). Thus, equation 11 for muscle becomes: 
F R-1* fl-1 Equation 7 
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The major source of error with this method, according to Gar1icl< (17), is the use of total free amino 
acid of the tissue to measure the specific activity at the site of protein synthesis. Some would 
argue that plasma free amino acids are a more appropriate measure because tRNA appears to be 
charged from this pool (26,53). This method has been used to measure protein synthesis in several 
species including cattle (30) and pigs (47). Synthesis rates in sheep for protein in several individual 
muscles have also been reviewed by Buttery (11). The fractional rate of synthesis (FSR) in the 
longissimus muscle varies from 0.02 to 0.06 in lambs depending on the study. While actual FSR's 
may vary with muscle type and technique used, in general, these methods appear to be sufficiently 
sensitive to measure small relative differences within a muscle type. 
Direct measure of protein degradation in muscle 
Unlil<e the variety of methods used to measure protein synthesis, methods to measure 
protein breakdown in vivo are quite limited. The only direct method to estimate proteolysis in vivo 
is to measure the excretion of 3-methylhistidine (3MH) in urine (37,56). 3MH is an amino acid 
specific to the contractile proteins actin and myosin and results from posttranslational modification 
of histidine residues at specific sites. After being released by peptide hydrolysis, 3MH is 
quantitatively excreted in the urine in most species. Urinary 3MH production can then be used as 
an indicator of the rate of muscle proteolysis in vivo. 3MH is not reincorporated into protein 
following degradation because specific tRNA is lacking (56). 
The application of the 3MH method depends on accurate collection of urine as well as 
quantitative excretion of 3MH in urine. This Is a problem In pigs and sheep, however, because large 
amounts of 3MH are trapped as the dipeptide balenine and retained in the muscle (37). Thus, 
output of 3MH in the urine was less than production from muscle protein breakdown (23,34). This 
problem with the 3I\4H in pigs and sheep as well as difficulties In quantitative urine collections might 
be overcome by developing a tracer method to measure 3MH release from protein. For example, 
compartmental modelling of a bolus Injection of deuterated 3MM tracer In plasma should 
theoretically indicate 3MH production In vivo. Development and validation of a plasma 3MH tracer 
method would represent a step forward In the use of 3MH to estimate muscle proteolysis by 
overcoming problems associated with accurate urine collection and provide a method to measure 
muscle proteolysis In sheep and swine. 
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SECTION I. RELATIVE ROLES OF PROTEIN SYNTHESIS AND PROTEOLYSIS IN 
STIMULATION OF MUSCLE GROWTH BY P-AGONISTS. 
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ABSTRACT 
The mechanism for p -agonist stimulation of muscle protein accretion is unclear. Some reports 
suggest an increase in protein synthesis while others suggest a decrease in protein breakdown 
depending on the doses and specific methodology used. Therefore, the objective of the present 
study was to determine the mechanism of action of the p -agonist L644969 on muscle protein 
deposition in young growing lambs using a combination of methods. 12 crossbred ram lambs were 
allocated to 2 treatments in a randomized block design (2 lambs per block, 6 blocks). Treatments 
were applied daily for 15 days: the p-agonist L644969 1 mg/kg feed per day feed, or control 
(carrier alone). During the last 10 days of the study, nitrogen balance was determined. During the 
last 5 days of treatment, the fractional breakdown rate of muscle protein was determined by 
compartmental analysis of plasma 3-methylhistidine kinetics using a bolus injection of [methyl-^Hg]-
3-methylhistidine. On the last day of the study, a 240 min primed dose constant infusion of [4,5-
^H]-leucine, [4,5-^Hg]-leucine, and [1-^^C]-phenylalanine was initiated. During the last 30 minutes 
of infusion, a flooding dose of [2,2,3-^H]-phenylalanine (2.0 mCi, 36.4 mmol, 180 ml) was given. 
At the end of infusion, the lambs were sacrificed. Longissimus dorsi and gastrocnemius muscles 
as well as liver were rapidly sampled and frozen. Radioactivity in protein bound and plasma leucine 
and phenylalanine were determined to estimate muscle protein synthesis, p -agonist increased 
nitrogen balance (11.3 g/d treated vs. 7.0 g/d control, p<0.05). Carcass weight and muscle 
weights of p-agonist-treated lambs were 5% and 13-22% greater (p<.05) than control lambs, 
respectively. Liver weights were unchanged. Plasma leucine and phenylalanine fluxes were not 
significantly altered. The fractional rate of myofibrillar protein breakdown tended to be lower in 
treated lambs (5.5 %/d, p-agonist vs 7.5 %/d controls p<.1). Fractional synthesis rates tended to 
be higher in the gastrocnemius muscie (treated: 4.75 %/d leu. 7.3 %/d phe, control: 3.90 %/d leu, 
5.6 %/d phe, p <.20 leu, p <.12 phe) but unchanged in the longissimus muscle (treated 2.88 %/d 
leu, 9.6 %/d phe; control: 2.93 %/d leu, 9.3 %/d phe, p > 0.8 leu and phe). Protein synthesis in 
the liver tended to be lower in p -agonist treated lambs relative to controls as estimated by the leu 
model (-22%, p<.17), but unchanged according to the phe model (-5%, p<.67). These observations 
suggest that the anabolic response to p -agonists may result from a decrease in protein breakdown 
and an increase in protein synthesis. The mechanism may vary among muscle types: the 
gastrocnemius may respond primarily by increasing protein synthesis while the longissimus may 
primarily respond by decreasing protein breakdown. 
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INTRODUCTION 
P -agonist administration siiifts growth toward more muscie and iess fat deposition in growing 
cattie (17,25,36), sheep (3,5,7,16,17,24), pigs (17,21,27) and poultry (11,17). In sheep, cimaterol has 
been reported to increase growth rate and feed efficiency by 13%, decrease carcass fat by 27%, 
and increase longissimus dorsi cross-sectional area by 17% (17). This shift to greater muscle mass 
is reflected by a rapid increase in nitrogen retention; up to 40% within 24 hours after administration 
(6,24,39). P -agonist anabolic action appears to be specific to skeletal muscle. P -agonists had no 
positive effect on growth of liver and kidney of rats (12,35), pigs (21), and lambs (23). Additionally, 
the increase in skeletal muscle size and weight appears to be due to increased hypertrophy rather 
than hyperplasia (4,23,39). 
In spite of the dramatic increase in muscle growth, as yet, there is no conclusive evklence that 
P-agonists act exclusively by increasing the rate of protein synthesis (1,10,12) or by decreasing 
protein breakdown (7,24,35). Most studies utilize In vivo isotope methods to directly assess protein 
synthesis, but generally proteolysis measurements are inferred. If no differences were observed in 
protein synthesis, by default it was assumed that proteolysis must be affected. More direct 
evidence for decreased protein breakdown is the reduced rate of 3-methylhistidine excretion (an 
estimate of muscie protein breakdown) observed in calves following clenbuterol treatment (40). In 
addition, reduced levels of proteinases also suggest a reduction in the rate of proteolysis (20,37). 
Thus, the indirect estimates of proteolysis, 3-methylhistidine excretion, and decreased protease 
levels all point to an involvement of proteolysis in p -agonist induced muscle growth. 
The objective of the present study was to directly assess protein synthesis and proteolysis in 
control animals and in animals treated with p -agonists. Additionally, two muscles and two isotope 
models were compared to determine the adequacy of muscle sampling and the models used. 
Sheep were chosen as a model because of the consistent large response to p -agonists and the 
ability to easily measure amino acid flux in the same animals. 
MATERIALS AND METHODS 
Animals 
Studies were conducted witli crossbred ram lambs (initial weight 27.9 kg) obtained from the 
same herd. Lambs were blocked according to weight and allocated randomly to treatments. All 
lambs were acclimated to the control diet and research environment for at least 7 days prior to 
study. During the study, lambs were fed twice daily. Lambs were weighed at the beginning of each 
period, and at the end of the study. 
Experimental Design 
The experiment was conducted as a randomized block design with 2 lambs per block and a 
total of 6 blocks. Nitrogen balance and stable isotopes fluxes were determined in all 6 blocks; 
radioisotopes and protein synthesis methods were used only in 5 blocks. Blocks of lambs were 
studied in a staggered arrangement such that the treatment periods started 5 days apart. All blocks 
of lambs were studied within a 6 week period and lambs were of similar weight at the time of study. 
On day 10 of treatment, each lamb was fitted with an indwelling jugular vein catheter for bolus 
injection of 3-methylhistidine tracer and plasma sampling. On day 16 of study, each lamb was fitted 
with a second jugular catheter for the constant infusion study. The 15 day treatment period (Figure 
1) consisted of 5 days while individually confined in pens followed by 10 days in metabolism crates. 
Urine and feces were collected dally during the metabolism crate period for nitrogen balance. 
Plasma 3-methylhistidine (3MH) kinetics were measured during the last 5 days of nitrogen balance 
by injecting a bolus of [methyl-^Hgj-SMH (D3-3MH) and determining plasma enrichment decay over 
a period of 5 days. 
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Figure 1. Scliematic of treatment period and final day of study. The 15 day treatment period 
consisted of 5 days in individual pens followed by 10 days in metabolism crates to 
determine nitrogen balance. Growth and feed intake were determined at the beginning 
and end of each period. Plasma 3MH kinetics were assessed by bolus injection of D^-
3MH followed by serial blood sampling. Plasma amino acid flux and tissue protein 
synthesis were determined on day 16. ^H-leu, Dg-leu, and ^^C-phe were administered by 
a 4-hour constant infusion. A ^H-phe flooding dose was given at time 210. Lambs were 
killed at 240 minutes. Tissues were rapidly sampled and frozen for later determination 
of specific activity bound in tissue protein. 
Nitrogen Balance 
Average daily nitrogen balance was determined as the difference between average daily intake 
nitrogen (Nj) and nitrogen excretion: fecal nitrogen (N^) and urinary nitrogen (NJ. 
Nitrogen balance (g/day) = N, - (N^ + N^) Equation 1 
Feed for each lamb was weighed into an individual preweighed container. Intake for each lamb was 
determined by measuring the decrease in weight of the feed plus container from the beginning to 
the end of each period. Feed nitrogen was determined by the Kjeldahl procedure. Urine was 
collected daily into 8 ml of 50% sulfuric acid in order to maintain acidic conditions. Each 24-hour 
collection was subsampled (5 % of total collected) and frozen. Daily urine samples for the nitrogen 
balance period were pooled for subsequent Kjeldahl nitrogen determination. Feces were collected 
daily, weighed and frozen. Total feces at the end of the period were subsampled for Kjeldahl 
nitrogen determination. 
Diet 
A complete pelleted ration (Table 1) was fed to prevent sorting of feed ingredients. The ration 
was balanced for metaboiizable energy (29). Net energy for gain (NEg) was 25% above 
requirement. Crude protein in the diet was elevated to 22% above NRC requirements such that 
protein synthesis would not be limited by intake of amino acids. Metaboiizable protein, however, 
was calculated to be 13% below the requirement for lambs of this size and growth rate (9,22). 
To assure that the treatments were consumed each day, the p-agonist L-644969 (Merck 
Sharpe and Dohme, Rahway, NJ) was added to each morning's feeding (1.4 mg dissolved In 5.0 
ml distilled water). The dosage was approximately 1.36 mg/kg of daily feed intake as lambs 
average daily feed intake was 1.03 kg. Control lambs were given 5 ml of distilled water as top-
dressing without p -agonist added. 
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Table 1. Composition of the basal diets (percent of total mix, as-fed) 
Ingredient Percent As-fed 
Corn, grain cracked 45.07 
Oats, grade 2 ground 20.01 
Soybean meal (expeiler) 20.01 
Dehydrated alfalfa 10.01 
Molasses (sugarcane) 3.00 
Limestone 0.75 
Dicalcium Phosphate 0.25 
Salt 0.25 
Vitamin premix 0.50 
Pell-aid 0.15 
Requirement Supplied by 
ration 
Daily intake (kg)® 1.58 1.58 
Metabolizable Energy (Meal)® 4.000 4.029 
Net Energy for Maintenance (Meal)® 0.718 0.718 
Net Energy for Gain (Meal)® 1.062 1.339 
Crude Protein (kg)® 0.216 0.264 
Metabolizable Protein (kg)'' 0.194 0.169 
Calcium (g)® 7.2 8.5 
Phosphorus (g)® 3.4 6.1 
^Calculated from National Research Council values (29). 
^Calculated from previously reported methods (9,22). 
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Kinetic analysis of 3-methylhistidine kinetics 
On day 11 of the treatment period (Figure 1), a bolus injection of Dg-SMH (30.35 ^md, MSD 
Isotopes, Rahway, NJ) was administered via jugular catheter. The catheter was thoroughly flushed 
with saline. Blood samples were taken periodically during the first 12 hours and daily for the next 
4 days after injection. Plasma enrichment of 3MH was determined by Gas Chromatography /Mass 
Spectrometry (see stable isotope quantitation). The time-course for decrease in plasma enrichment 
was fit to a 3-pool model using the Simulation Analysis and Modelling (SAAM) computer modelling 
program as described previously (31-33). 
Constant infusion and sampling protocol 
All isotopes were dissolved in normal saline just prior to Infusion. In all cases, the isotopes 
were given in a primed dose (20X infusion rate for 1 min) constant infusion (0.1 ml/min). Table 2 
shows the infusion rates and approximate doses. All lambs received stable isotope tracers. Only 
5 blocks of lambs received radio-labelled tracers. Plasma was sampled at 0, 60, 90,120, 150, 180, 
210, 220, 230 and 240 minutes from the jugular vein opposite that of infusion. The 210 min plasma 
sample was taken just prior to the flooding phe dose. The phe flooding dose was prepared by 
o 
dissolving 36.5 mmol unlabelled phe in 180 ml distilled water, and adding 2 mCi H-phe. The 
solution was warmed to achieve complete solubility, cooled to approximately 4(f C, and then rapidly 
injected into the jugular vein via the infusion catheter, i^mbs were killed by lethal injection of T-61 
(DVM Supply, Spencer, lA) exactly 30 minutes after the phe flooding dose. Approximately 5g 
samples of longissimus and gastrocnemius muscles as well as liver were Immediately dissected and 
frozen in liquid nitrogen for later analysis. 
36 
Table 2. Isotopic tracers used 
Tracer Infusion rate Approximate dose 
[4,5-^H]-leucine® 100000 dpm/kg-min 340 //Ci 
[4,5-^Hg]-leucine'' 0.06 /zmol/kg-min 490 /zmoi 
[1-^^C]-phienylalanine^ 0.06/imol/kg-min 490 //mol 
[2,3,3-^H]-phenylalanine® 2 mCi bolus 2 mCi, 36.5 mmol" 
®iCN Radiochemicals, Irvine, CA. 
''Tracer Technologies, Somerville, MA. 
^Flooding dose of unlabelled phenylalanine, Sigma, St. Louis, MO. 
Plasma amino acid specific activity 
Plasma leucine specific activity was determined by HPLC and liquid scintillation counting by 
the method of Nissen et al. (30). Phenylalanine (phe) was isolated from plasma similar to leucine 
(30). Phe, however, was analyzed directly as free amino acid because oxidation of phe to a-
ketopyruvate results in loss of tracer from phe. Plasma amino acids were isolated using a small 
cation exchange column. The eluent from cation columns was dried and dissolved in a small 
volume of neutral phosphate buffer. Phe was isolated on a C-18 reversed phase analytical column 
(IBM Instruments, Inc.) using an isocratic gradient of 7.7% acetonitrile in 0.1 M phosphate buffer. 
Phe elution was monitored at 254 nm using a variable wavelength detector (Perkin Elmer LC75). 
The phe peak had a retention time of 6.3 min and was quantitated using computer integration. 
Radioactivity in the collected phe peak eluent was determined by liquid scintillation counting. Phe 
specific activity declined linearly from 220 to 240 min (data not shown). Thus, a line relating phe 
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specific activity to time was fit by linear regression using time 220, 230, and 240 min samples for 
each lamb. The average phe specific activity for the flooding dose period (210 to 240 min) was 
then calculated as the specific activity of plasma at 225 min for each lamb. 
Protein bound leu and phe in muscle and liver 
Tissue (~5 g) was suspended in liquid nitrogen and freeze-ground to a fine powder using a 
Waring blender. Samples of freeze-ground tissue (2 g) were subsequently homogenized In 5 ml 
deionized water with a Polytron tissue homogenizer and the proteins precipitated by adding 5 ml 
of 3.0N perchloric acid (Fisher). Proteins were pelleted by centrifugation (1900 X g) for 10 min, the 
supernatant was discarded, and the protein peliet rinsed by 2 successive washings in 6 ml of 0.5N 
perchloric acid. Proteins again were collected in a pellet after centrifugation at 480 X g for 10 min. 
Proteins were hydrolyzed according to previously described methods (34) in 15 ml of 6.0N HCI at 
110° C for 6 hours. Amino acids from hydrolysis were isolated by cation exchange chromatography 
as described for plasma. The eluate from cation columns was split between the leu and phe 
specific activity assays (half for each). Leucine was converted to KIC by Incubation with amino acid 
oxidase (1.0 mg/ml in 0.5M Tris buffer pH 7.8) for 4 hours. KIC was Isolated from the oxidation 
mixture by extraction with methylene chloride as outlined above for plasma. Keto acids were 
resolved on a Dynamax C-18 reversed phase prep column (21.4 mm X 25 cm, Rainin Instruments, 
Emeryville, CA) using an isocratic buffer of 10% acetonitrile in 0.02M phosphate buffer pH 7.0. KIC 
exhibited a retention time of 8.3 min at a flow rate of 14 ml/min. Peaks were detected using a 
variable wavelength detector (Perkin Elmer) at 214 nm, and quantitated by computer integration. 
The Mmol of KIC in each peak was calculated by comparison to peaks resulting from KIC standards 
of similar concentration. Radioactivity of the collected KIC peak was determined by liquid 
scintillation counting. Plie was analyzed witliout conversion to its keto acid. Eluate from the cation 
columns was dried under a gentle stream of nitrogen gas at 60° C. The residue was dissolved in 
340 /zl of 0.1 M phosphate buffer pH 7.0 and transferred to a microfuge tube. Insoluble particulate 
matter was pelleted by microcentrifugation for 2 minutes. Phe was chromatographed under the 
same conditions using the same buffer as leu as described above only with detection at 254 nm. 
Phe retention time was approximately 7.4 min. The /xmol of phe in each peak was determined by 
comparison to standards chromatographed under the same conditions. Radioactivity of each peak 
was determined by scintillation counting of collected eluate. 
Measurement of stable isotope enrichment in plasma 
Isotopic enrichment of leucine and phenylalanine samples were determined by gas 
chromatography-mass spectrometry on a Hewlett Packard GCMS system (5890/5970). A 25m X 
0.2mm crosslinked methylsilicone capillary column (0.11um film thickness) with a column flow rate 
of 1 ml/min was used. Temperature ramps were 50-20(f C at 4(f C/min (held at 20(f C for 0.8 
min) and 200-300° C at 6Cf C/min. Leucine and phenylalanine peaks were quantitated in the same 
run. Leucine eluted at 6.3 minutes while phenylalanine eluted at 8.6 minutes depending on actual 
column length and age. Using the MTBSTFA derivative (Regis Chemical, Morton Grove, IL), the 
major base ion (M) of leucine and phenylalanine were monitored at m/z = 302. D^-ieu was 
monitored at m/z = 305; ^^C-phe was monitored at m/z = 303. A major ion fragment of natural 
3MH was monitored at m/z = 238. Peaks for each ion were quantitated using computer integration 
(Hewlett Packard Chemstation) based on peak height. Isotopic enrichment in M + 1 (^^C), and M+3 
(Dg) were corrected for natural background enrichment by subtracting M + 1 and M+3 enrichments 
observed in time 0 samples which were collected before isotope infusion. 
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Calculations 
Plasma leucine and phenylalanine flux were calculated from the formula 
F = l/Sp Equation 2 
where F is the flux O:imol/kg-min), I is the infusion rate Oumol/l<g-mln or dpm/kg-min) and Sp is 
the enrichment (atoms percent excess) or specific activity {dpm//zmol) of the tracer in plasma at 
plateau. 
Protein synthesis in tissues based on constant infusion of ^H-leu was calculated as described 
previously (15) from the formula 
S ~ K-rK* Equations 
where is the specific activity of leucine bound in tissue protein, S, Is the specific activity of 
leucine in intracellular fluid, K, is the rate constant for rise in specific activity of intracellular leucine, 
and Kg is the fractional synthesis rate (FSR). For muscle, RK^ was used as an approximation for 
Kj where R is the ratio of protein-bound leucine to intracellular leucine in muscle (15). R was taken 
to be 550 based on previous work (13,38). For liver, K, is nearly equal to or the rate constant 
for rise in specific activity in plasma. Because FSR is relatively insensitive to the actual value of K^, 
and because should be relatively constant across lambs, Kp was estimated as 80 d"^ from the 
shape of the piasma enrichment curve. The absolute rate of protein synthesis (ASR) in g/day was 
calculated as 
ASR = (FSR) P Equation 4 
where P is the estimated grams of protein in the whole organ. P was estimated by assuming 20% 
of whole organ weight was protein. 
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Protein synthesis based on the phe flooding dose method was calculated according to 
previously reported equations (2,14) 
S^/Sj = Kgt Equation 5 
where t is the time of flooding dose. S| was taken as the average specific activity of phe in plasma 
over the flooding dose period. 
Fractional breakdown rate (FBR) was calculated using the 3-methylhistidine production rate (PR 
//mol/day) as estimated by the kinetic compartmental model and total muscle 3-methylhistidine 
content (C //mol) by the formula: 
FBR = PR/C Equation 6 
C was estimated by determining the 3-methylhistidine content in longissimus muscle and 
extrapolating to total muscle 3-methylhistidine. Total muscle was estimated by total dissection of 
carcass muscle in 6 lambs. This was related to the average weight of the longissimus, 
gastrocnemius and psoas muscles by linear regression. Total carcass muscle in the remaining 
lambs was then estimated using this regression equation along with the average weight of these 
3 muscles. 
Net protein accretion (NPA) for each muscle was estimated by the following equation: 
NPA = FSR - FBR Equation 7 
FSR was derived from the leu or phe model and FBR was derived from the 3MH compartmental 
model. This parameter was used to assess the relative differences in protein accumulation in 
muscle due to p -agonist administration. 
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RESULTS AND DISCUSSION 
Nitrogen Balance 
The effects of the p -agonist 1644969 on nitrogen retention, carcass weight and individual organ 
weights are shown in Table 3. P -agonist administration improved whole-body nitrogen retention as 
nitrogen balance increased by 4.3 g/d or 60% (p<.06) relative to controls. This is consistent with 
previous reports which have suggested a 30-40% increase in nitrogen retention within the first 24 
hours of study (6,24,39). Assuming nitrogen accounts for 16% of protein weight on average, and 
muscle is 20% protein by weight, this improvement in nitrogen balance can be related to 26.9 g/d 
more body protein and 134.4 g/d total muscle deposited. Thus, over the 15 day treatment period, 
the increase in nitrogen balance if directed toward muscle growth would result in 2 kg more muscle 
deposited in p -agonist treated lambs compared to control lambs. 
Muscle Weights 
Consistent with the increase in nitrogen balance, individual muscles of p -agonist-treated lambs 
were 12 to 22 % larger (p<.04) than controls (Table 3). Liver weight was not significantly altered 
by p -agonist treatment. These changes in muscle weights are also consistent with previous studies 
which have demonstrated muscle weight increases with p-agonist administration (5,7,23). For 
example, cimaterol treatment resulted in a 12 to 35% increase (p<.05) in biceps femoris, 
semimembranosus, semitendinosus, triceps brachii, infraspinatus, and supraspinatus muscle 
weights of lambs (5). Another study showed a 40% increase in gastrocnemius weight in lambs fed 
cimaterol (23). In lambs treated with clenbuterol, iongissimus dorsi and vastus lateralis muscles 
were 29% heavier in treated lambs than control lambs (p<.05) while the vastus Intermedlus showed 
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Table 3. The effect of p -agonist administration on nitrogen balance and tissue weights 
Parameter Control P -Agonist® SEM" P>f 
Percent 
Change*^ 
Nitrogen Balance (g/d)® 7.0 11.3 0.589 0.057 60.76 
Live wt (kg) 30.23 30.76 0.219 0.935 1.75 
Carcass wt (kg)' 14.10 14.88 0.104 0.039 5.51 
Longissimus Dorsi (g) 354.8 400.2 5.94 0.037 12.78 
Gastrocnemius (g) 102.5 117.7 1.73 0.018 14.80 
Psoas Major (g) 63.3 77.5 1.426 0.008 22.37 
Liver (g) 781.5 706.5 16.87 0.205 -9.60 
®The p -agonist L644969 was administered at 1 mg/kg of feed as top dressing daily for 
15 days prior to isotope studies and slaughter. 
^Standard Error of the Mean. 
^Probablility of a greater t-statistic based on simple t-test. 
^Percent difference between p -agonist treated lambs and control lambs. 
^Nitrogen balance was determined during the last 10 days of p-agonist administration. 
^Lambs were sacrificed on day 16 of P-agonist administration following completion of 
isotope infusion studies. Individual organs were dissected and weighed. 
no significant change (7). These data and the present study indicate that p -agonist stimulates 
muscle growth, but the response can vary with the muscle type. 
Live Weight and Carcass Weight 
Live weight was unchanged by L644969 treatment in the present study (Table 3), but carcass 
weight was increased by 5% (p<.04). Previous studies with cimaterol and cienbuterol also show 
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no change in live weight (3,5,16,20), and small increases in carcass weight (3,5,16). 
Understandably, changes in live and carcass weight may be complicated because p-agonist 
administration increases muscle mass at the expense of fat (both which contribute to live and 
carcass weight). 
Amino Acid Flux 
The effects of the p -agonist L644969 on plasma amino acid flux are shown In Table 4. Plasma 
leucine (leu) and phenylalanine (phe) flux were measured after a 240 minute primed constant 
infusion of amino acid tracers. Flux was determined as infusion rate/ enrichment or specific activity 
at plateau. Plateau was reached in all cases by 90 minutes of infusion. Estimates of plasma leucine 
flux varied depending on the tracer used. The ^H-leu tracer method gave an estimate of 11-13 
/zmol/kg-min while the D^-leu tracer gave an estimate of 7 /zmol/kg-min. These values are high 
in relation to previous reports (19), but the difference may be due to the fact that, in the current 
study, lambs were in the fed state rather fasted for a 10-12 hour period. No significant change was 
noted in plasma leucine flux due to p -agonist treatment. One previous report, however, suggested 
a transient increase in leu flux over a similar treatment period in lambs fed clenbuterol (24). Leu 
flux was increased by 15% (p<.001) on day 11 of treatment, but neutral on days 4 and 18. It is 
unclear whether these transient changes in amino acid flux reflect a transient increase in protein 
synthesis in muscle or a differential contribution of individual organs to whole body protein synthesis 
and breakdown during the treatment period. 
Overall, it appears that L644969, like cimateroi and clenbuterol, has little effect on plasma 
amino acid flux. Authors have maintained that unaltered amino acid flux indicates that p -agonists 
increase protein accretion by decreasing protein breakdown rather than increasing protein synthesis 
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Table 4. The effect of p -agonist administration on plasma amino acid flux 
D„-leu 
APE* 
i^C-phe 
APE* 
^H-leu 
Flux" 
D.-leu 
Fllx" 
0) 3-MH 
FBR° 
Control 0.0106 0.0457 12.9 7.1 1.57 7.5 
P -agonist'' 0.0115 0.0466 11.1 7.0 1.48 5.5 
SEM® 0.001146 0.002717 0.499 0.468 0.1128 0.345 
P>t^ 0.082 0.915 0.309 0.938 0.802 0.109 
Percent 
Change^ 8.66 2.02 -14.03 -1.65 -5.76 -26.60 
*Atoms Percent Excess measured at plateau during a 240 min primed constant infusion 
of tracers. Dyleu and ^^C-phe were infused each at 0.06 //mol/kg-min. ^H-leu was infused 
at "100000 dpm/kg-min. 
^Plasma amino acid flux ^mol/kg-min) calculated as tracer infusion rate/ plasma APE 
or specific activity at plateau. Plasma H-leu specific activity is presented in Table 5. 
^Fractional Breakdown Rate based on 3-methylhistidine kinetics measured by bolus 
injection and compartmental analysis during the 5 days prior to leu and phe kinetic studies. 
''The p -agonist L644969 was administered at 1 mg/kg of feed as top dressing daily for 
15 days prior to leu and phe kinetic studies. 
^Standard Error of the Mean 
'Probablility of a greater t-statistic based on simple t-test. 
^Percent change of p -agonist treatment relative to control. 
(7,24,35). This conclusion may be reasonable, but can not be stated with confidence without 
considering the relative contributions of both synthesis and breakdown because both of these 
processes contribute to plasma amino acid flux. 
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Whole-body Muscle Protein Breakdown 
The use of plasma 3-methylhistidine (3MH) kinetics in the present study aliows a direct 
estimate of muscle protein breakdown (28,41). 3MH is an amino acid specific to the contractile 
proteins actin and myosin resulting from post-translational methylation on histidine residues. When 
the protein is degraded, 3MH is released and not reutilized for protein synthesis because specific 
tRNA is lacking. Thus, 3MH excretion in the urine has been used as an indicator of myofibrillar 
protein breakdown in species like cattle and humans. In sheep and swine, however, 3MH excretion 
in urine is less than total 3MH release from protein breakdown because the free 3MH combines with 
P-alanine to form a dipeptide (balenine) which is retained by muscle (18,26). To make the 3MH 
technique useful in swine and sheep, recent studies have suggested that 3MH production rate can 
be estimated from compartmental analysis of plasma 3MH kinetics (31-33). 
The estimates of fractional breakdown rates determined from 3MH compartmental analysis in 
P -agonist and control lambs are shown in Table 4. Lambs treated with p -agonist tended to exhibit 
a lower fractional breakdown rate relative to controls (-27%, p<.11). This observation is supported 
by previous work in calves which has shown a 26 to 40% decrease in fractional breakdown rate 
estimated by urinary SMH excretion (40). Thus, the concept of P-agonists decreasing whole-body 
muscle protein breakdown is consistent with previous work and data in the present study. 
Tissue Protein Synthesis 
The specific activities of leu and phe in plasma and tissue protein are summarized In Table 5. 
These values were used to calculate the fractional synthesis rates (FSR, %/d) and absolute 
synthesis rates (ASR, g/d) in individual muscles and liver according to the equations 3 and 4 above. 
No significant treatment differences were observed In the specific activity of free leu and phe in 
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Table 5. Summary of specific activity of leu and phe in plasma, liver, and skeletal muscle 
Control P -Agonist'' Percent 
Model® SA SA SEM° p>t'' Change® 
Plasma' leu 8120 8980 268 0.361 10.61 
phe 80500 84600 1467 0.423 5.17 
Longlssimus^ leu 27.4 29.4 1.401 0.695 7.03 
phe 155 167 8.287 0.677 7.80 
Gastrocnemius^ leu 39.4 55.3 1.698 0.013 40.62 
phe 93 126 4.669 0.053 35.78 
Lwefi leu 494 433 18.504 0.353 -12.34 
phe 502 497 14.489 0.917 -1.05 
®ln the leu constant infusion model ^H-leu was administered by primed dose constant 
infusion for 240 minutes at a rate of 100000 dpm/min. The phe flooding dose model 
consisted of 2.0 mCi of ^H-phe was given along with 36.5 mmol unlabelled phe in a 180 ml 
bolus injection at time 210 min. 
Lambs received the p-agonist L644969 daily for 15 days prior to isotope studies at 1 
mg/kg feed. 
''standard Error of the Mean 
^Probablility of a greater t-statistic based on simple t-test. 
^Percent change of P -agonist treated lambs relative to controls. 
'specific activity of free leu and phe in plasma (dpm//izmol). Plateau leucine specific 
activity was determined by serial sampling of plasma between 0 and 210 min. Plasma phe 
specific activity showed a linear decrease from 210 to 240 minutes. Therefore, average phe 
specific activity is shown. At 240 minutes, lambs were sacrificed, and tissues were rapidly 
sampled and frozen. The specific activity of each tracer bound in tissue protein was 
determined. 
"Specific activity of leu and phe bound in tissue protein (dpm/umd). 
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plasma. Protein-bound leu and phe specific activities in longlssimus muscle and liver were also 
similar among treatments. In the gastrocnemius muscle, however, specific activities of protein-
bound leu and phe were ~35% greater (p<.05) in P-agonist treated lambs compared to controls. 
Similar changes were observed in the muscle FSR's and ASR's calculated from these values 
(Figure 2). As shown in Figure 2A, the p -agonist did not significantly affect the FSR of longisslmus 
dorsi muscle (P-agonist vs control; -1.71% leu +2.84% phe, p>0.8). The FSR of gastrocnemius 
muscle also was not significantly affected, but it tended to be greater in treated lambs (P -agonist 
vs control: +21.63% leu, p<.21; +31.44% phe, p<.12). The disparity between the actual values of 
the leu and phe models (Fig. 2A) are likely due to differences in precursor pool specific activity. 
Flooding dose techniques typically give higher FSR values than constant infusion techniques (2,8) 
which may be attributed to intracellular specific activity being closer to plasma specific activity in 
the phe model as compared to the leu model. Previous reports have suggested that intracellular 
specific activity in the leu model may be only 60% of plasma specific activity. Thus, if intracellular 
specific activity were used to calculate protein synthesis In the leu model, the actual rate would be 
1.6 times as great as reported in Figure 2. In practice, however, the relative differences between 
P -agonist and control lambs may be more important than the actual FSR's. 
The FSR was then used to calculate ASR by multiplying the fractional rate by the amount of 
protein in the muscle according to the equations outlined above. Longissimus muscle ASR 
estimates (Figure 2B) were numerically higher for treated lambs than control lambs (P -agonist vs 
control; +11.82% leu, p=.61: +16.67% phe, p=.36), but treatments were not statistically different. 
A large increase was observed in the ASR of gastrocnemius muscle (P -agonist vs control; +37.00% 
leu, p=.04: +48.10% phe, p=.03). Thus, the response of protein synthesis appears to differ 
between muscles even though muscle weight gains were similar. This suggests that: 1) the models 
Figure 2. Muscle protein synthesis. Protein synthesis was measured in the longissimus and 
gastrocnemius muscles by two models: ^H-leu constant infusion (leu) and ^H-phe 
flooding dose (phe). See Materials and Methods for details of calculation methods. P 
values indicate differences between p -agonist treated lambs and controls. The standard 
error of the mean for each muscle and model is denoted by standard error bars on each 
respective control treatment. 
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are measuring different events in each muscle; or 2) the muscles grew by different mechanisms. 
The increase in longissimus muscle weight was apparently due entirely to a decrease in protein 
breakdown because protein synthesis was unchanged in this muscle and overall muscle protein 
breakdown tended to be decreased. In the gastrocnemius, however, the increase in muscle weight 
apparently resulted from an increase in synthesis and an increase in protein breakdown because 
gastrocnemius FSR tended to be higher and overall muscle FBR tended to be lower in p -agonist 
lambs relative to controls. Similar differential responses have been noted in lambs fed clenbuterol 
(7). In that study, the iongissimus muscle weight was 29% greater(p<.05), but the FSR measured 
by tyrosine constant infusion was -5% (not significant) in treated lambs relative to controls. The 
vastus lateralis weight in treated lambs was 19% greater (p<.05), and FSR, although not significant 
at p<.05 was +30% relative to controls. The vastus intermedlus showed little change in either 
muscle weight or FSR. Certainly, this differential protein synthetic response among specific muscles 
warrants further study to determine if it is methodological in nature or if true mechanistic differences 
exist between different muscle types. 
In order to describe the overall effect on growth in terms of isotopic models, net protein 
accretion (NPA) was calculated for each muscle as the difference of FSR and FBR (Figure 2C). 
Regardless of the isotope model or muscle, NPA tended to be greater in p -agonist treated lambs 
relative to controls. The treatment difference was significant at p<.05 in the gastrocnemius muscle 
using the phe model. The leu method exhibited negative NPA because the absolute rate for FBR 
exceeded FSR. NPA based on phe FSR was higher because phe FSR values were higher in 
relation to leu FSR values. Knowing that protein balance was positive based on nitrogen balance, 
this suggests that isotopic models may be more useful In defining relative differences between 
treatments than in defining the absolute rates of protein accretion. 
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Liver protein synthesis 
In addition to changes in muscle protein turnover, involvement of other important metabolic 
organs may also be important even though the //eight of these organs appears to be unchanged. 
The relative changes in liver FSR and ASR are shown in Figure 3. The FSR (Figure 2A) tended to 
be lower In P-agonist treated lambs as estimated by the leu model (-22%, p=.17), but FSR was 
unchanged as measured by the phe model (-5%, p=.67). Similarly, liver ASR was reduced in 
treated lambs vs controls (-32% leu, p=.05; -17% phe, p=.22). The potential negative effects on 
liver protein synthesis have not been previously predicted. 
In conclusion, the relative roles of protein synthesis and proteolysis in mediating the anabolic 
effects of p -agonists in muscle may vary among muscle types. Muscles like the gastrocnemius 
may respond primarily by increasing protein synthesis while muscles like the longisslmus may 
primarily respond by decreasing protein breakdown. These changes may not be reflected in 
estimates of whole-body protein turnover (like plasma amino acid flux) because muscle types may 
respond differently and protein turnover in other metabolically Important organs like the liver may 
be altered. P -agonists appear to decrease proteolysis in vivo and possibly increase protein 
synthesis. Unfortunately, proteolysis in individual muscles can not be measured in vivo. Thus, 
conclusions relative to exact mechanisms of increased muscle hypertrophy can not be determined. 
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Fractional synthesis rate (*/d) 
• CONTROL  ^BETA 
Absolute synthesis rate (g/d) 
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Figure 3. Uver protein synthesis. Liver protein synthesis was measured by two models: ^H-leu 
constant infusion (leu) and ^H-phe flooding dose (phe). See Materials and Methods for 
details of calculation methods. P values indicate difference between p -agonist treated 
lambs and controls. The standard error of the mean for each model is denoted by the 
standard error bar on the respective controls for each parameter. 
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phenylalanine, Dg-leu: [5,5,5-^Hg-leucine, C-phe: [1-^^Cl-phenylalanine,3MH:3-methylhistidine, Dy 
3MH: [methyl-^Hg-]3-methylhistidine, FBR: fractional breakdown rate (%/d), FSR: fractional 
synthesis rate (%/d), ASR: absolute synthesis rate (g/d), KIC: a-ketoisocaproic acid. 
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ABSTRACT 
Nitrogen balance, amino acid flux, tissue protein synthesis, creatinine excretion and 3-
methylhistidine excretion are all used to measure protein metabolism, but have rarely have they 
been directly compared. The objectives of the present study were to 1) directly compare constant 
infusion and large dose flooding techniques for measuring muscle and liver protein synthesis, and 
2) determine which protein models alone or In combination best predict total muscle mass. 36 
crossbred ram lambs were studied in a randomized block design with 6 lambs per block. After an 
adjustment period, 10-day nitrogen balance was determined. 3-methyihistidine kinetics were 
measured by bolus injection of [methyl-^Hg]-3-methylhistidine along with compartmental modeling 
during the last 5 days of nitrogen balance. Creatine excretion was also determined during this 
period. Plasma amino acid flux and tissue protein synthesis were determined on the day following 
nitrogen balance. Amino acid flux was determined by constant infusion of [4,5-^H]-leucine, [4,5-
^Hg]-leucine, and [1-^^C]-phenylalanine. Protein synthesis in the longissimus and gastrocnemius 
muscles as well as liver was measured by using the ^H-leucine tracer by constant infusion and also 
by a [2,3,3-^H]-phenylalanine flooding dose method. Lambs were sacrificed following study and 
individual muscles were dissected and weighed. Longissimus dorsi, gastrocnemius, and psoas 
major muscles together were used as an indicator of total muscle weight. The fractional synthesis 
rate (FSR) of tissue protein was calculated according to previously established formulas. The 
constant infusion (leu) and flooding dose (phe) models were evaluated by correlation analysis and 
the relationship of tissue FSR to total muscle weight. Leu FSR's were correlated among organs 
(R=.5 to .6, P<.005) whereas phe FSR's were unrelated among organs. FSR's measured by leu 
and phe techniques were unrelated within a tissue. These data indicate that methodological 
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differences exist between these tissue protein synthesis models. The individual parameters of 
creatinine excretion (R = 0.42), phe flux (R = -0.39), and 3MH pool 3 (R = .33) were significantly 
(P<.05) correlated to total muscle mass. Multiple regression analysis, however, showed that a 
combination of phe flux, along with liver and gastrocnemius FSR (flooding dose method) gave the 
best overall correlation to total muscle mass (R = 0.71). In conclusion, a technique which 
measures plasma phe flux along with tissue protein synthesis should give better overall information 
about muscle protein accretion than any of the commonly used techniques when used 
independently. 
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INTRODUCTION 
Muscle mass is controlled by many factors, but on a fundamental level it is regulated by 
the balance of protein synthesis minus protein breakdown. Consequently, to determine whether 
muscle mass is altered by changes in protein synthesis or proteolysis, methodology must exist to 
measure these processes in vivo. Several techniques have been developed to study protein 
synthesis and degradation in specific organs and tissues. In general these methods introduce an 
isotopically labelled tracer amino acid into the plasma pool and measure tracer incorporation into 
tissue proteins. To date, the primary models for measuring tissue protein synthesis have not been 
directly compared: large dose (1,7,12,22) and constant infusion (2,5,23). Indirect comparisons 
between studies suggest the fractional synthesis rate of tissues are typically much higher for the 
flooding dose method than the constant infusion method. Whether this is due to actual differences 
in the models or due to differences in experimental technique is unknown. 
In contrast to a variety of techniques to measure protein synthesis in vivo, the methods to 
measure proteolysis in vivo are very limited. The only muscle-specific method to measure protein 
degradation currently available is to measure urinary excretion of 3 methylhistWine (3MH)(15,27). 
While this model is useful in studying protein breakdown in humans and cattle, its use in sheep and 
swine is limited because urinary 3MH excretion Is not quantitative (9,14). The method is also limited 
because it only measures the rate of protein breakdown without any indication of muscle mass. 
Recently, however, a kinetic model of 3MH metabolism has been developed (18-20). In this model, 
3MH kinetics as well as pool sizes can be estimated. Therefore, this kinetic model has the 
possibility of estimating muscle protein breakdown as well as muscle mass. 
The objectives of the present study were: 1) directiy compare constant infusion and 
flooding dose methods for protein synthesis In a large number of animals and in several tissues; 
and 2) determine if measures of protein synthesis and proteolysis alone or in combination can 
indirectly predict muscle mass. Together these studies should establish the relative value of the 
constant infusion and flooding dose methods for measuring in vivo protein synthesis. 
MATERIALS AND METHODS 
Animals 
Studies were conducted with a total of 36 crossbred ram lambs (initial weight 27.9 kg) 
obtained from the same herd. Lambs were blocked according to weight and allocated randomly 
to treatments. All lambs were acclimated to the control diet and research environment for at least 
7 days prior to study. During the study, lambs were fed twice daily. Lambs were weighed at the 
beginning of each period, and at the end of the study. 
Experimental Design 
The experiment was conducted as a randomized block design with 6 lambs per block and 
a total of 6 blocks. Nitrogen balance and stable isotopes fluxes were determined in all 6 blocks; 
radioisotopes and protein synthesis methods were used only In 5 blocks. Blocks of lambs were 
studied in a staggered arrangement such that the treatment periods started 5 days apart. All blocks 
of lambs were studied within a 6 week period and lambs were of similar weight at the time of study. 
On day 10 of treatment, each lamb was fitted with an indwelling catheter in a jugular vein for bolus 
injection of 3-methylhistidine (3IVIH) tracer and plasma sampling. On day 16 of study, each lamb 
was fitted with a second jugular catheter for the constant infusion study. The 15 day treatment 
period (Figure 1) consisted of 5 days while individually confined in pens followed by 10 days in 
metabolism crates. Urine and feces were collected daily during the metabolism crate period for 
nitrogen balance. Plasma 3MH kinetics were measured during the last 5 days of nitrogen balance 
by injecting a bolus of [methyl-^Hg]-3MH (Dg-SMH) and determining plasma enrichment decay over 
a period of 5 days. 
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Figure 1. Schematic of treatment period and final day of study. The 15 day treatment period 
consisted of 5 days in Individual pens followed by 10 days in metabolism crates to 
determine nitrogen balance. Growth and feed intake were determined at the 
beginning and end of each period. Plasma 3MH kinetics were assessed by bolus 
injection of D3-3MH followed by serial blood sampling. Plasma amino acid flux and 
tissue protein synthesis were determined on day 16. ^H-leu, D^-leu, and ^^C-phe 
were administered by a 4-hour constant infusion. A ^H-phe flooding dose was 
given at time 210. Lambs were killed at 240 minutes. Tissues were rapidly 
sampled and frozen for later determination of specific activity bound in tissue 
protein. 
Diet 
A complete mixed pelleted ration (Table 1) was fed to prevent sorting of feed ingredients. 
The ration was balanced for metabolizable energy (16). Net energy for gain (NEg) was 25% above 
requirement. Crude protein in the diet was elevated to 22% above NRC requirements such that 
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Table 1. Composition of the basal diets (percent of total mix, as-fed) 
Ingredient Percent As-fed 
Corn, grain cracked 45.07 
Oats, grade 2 ground 20.01 
Soybean meal (expeller) 20.01 
Dehydrated alfalfa 10.01 
Molasses (sugarcane) 3.00 
Limestone 0.75 
Dicalcium Phosphate 0.25 
Salt 0.25 
Vitamin premix 0.50 
Pell-aid 0.15 
Requirement Supplied by ration 
Daily intake (kg)® 1.58 1.58 
Metabolizable Energy (Meal)® 4.000 4.029 
Net Energy for Maintenance 0.718 0.718 
(Meal)® 
Net Energy for Gain (Meal)" 1.062 1.339 
Crude Protein (kg)® 0.216 0.264 
Metabolizable Protein (kg)'' 0.194 0.169 
Calcium (g)® 7.2 8.5 
Phosphorus (g)® 3^4 6J 
"Calculated from National Research Council values (National Research Council, 1985) 
^Calculated according to previously established methods (4,11). 
protein synthesis would not be limited by intake of amino acids. Metabolizable protein, however, 
was calculated to be 13% below the requirement for lambs of this size and growth rate (4,11). 
Nitrogen Balance 
Average daily nitrogen balance was determined as the difference between average daily 
intake nitrogen (Nj) and nitrogen excretion: fecal nitrogen (N,) and urinary nitrogen (NJ. 
• Nitrogen balance (g/day) = N. - (N^ + N,) Equation 1 
Feed for each lamb was weighed into an individual preweighed container. Intake for each lamb was 
determined by measuring the decrease in weight of the feed plus container from the beginning to 
the end of each period. Feed nitrogen was determined by the Kjeldahl procedure. Urine was 
collected daily into 8 ml of 50% sulfuric acid in order to maintain acid conditions. Each 24-hour 
collection was subsampled (5% of total collected per day) and frozen. Daily urine samples for the 
nitrogen balance period were pooled for subsequent Kjeldahl nitrogen determination. Feces were 
collected daily, weighed and frozen. Total feces at the end of the period were subsampled for 
kjeldahl nitrogen determination. 
Kinetic analysis of 3-methylhistidine kinetics 
On day 11 of the treatment period (Figure 1), a bolus injection of Dg-SMH (30.35 /.imol, 
MSD Isotopes, Rahway, NJ) was administered via jugular catheter. The catheter was thoroughly 
flushed with normal saline. Blood samples were taken periodically during the first 12 hours and 
daily for the next 4 days after injection. Plasma enrichment of 3MH was determined by Gas 
Chromatography /Mass Spectrometry (see stable isotope quantitation). The time-course for 
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decrease in piasma enricliment was fit to a 3-pool model using the Simulation Analysis and 
Modelling (SAAM) computer modelling program as described previously (18-20). 
Creatinine excretion 
Creatinine excretion was determined in pooled urine samples collected during the last 5 
days of nitrogen balance. Creatine concentration in the urine was determined by a colorimetric 
assay kit (Sigma, St. Louis, MO) using a Beckman Model B spectrophotometer. Total excretion was 
calculated as creatinine concentration times total urine collected over the period. 
Constant infusion and sampling protocol 
All isotopes were dissolved in normal saline just prior to infusion. In all cases, the isotopes 
were given in a primed dose (20X infusion rate for 1 min) constant infusion (0.1 ml/min). Table 2 
shows the infusion rates and approximate doses. All lambs received stable isotope tracers. Only 
5 blocks of lambs received radio-labelled tracers. Plasma was sampled at 0, 60, 90, 120, 150, 180, 
210, 220, 230 and 240 minutes from the jugular vein opposite that of infusion. 
Table 2. Isotopic tracers used 
Tracer Infusion rate Approximate dose 
[4,5-^H]-leucine® 100000 dpm/kg-min 340 //Ci 
[4,5-^Hg]-leucine^ 0.06 /imol/kg-min 490 //mol 
[ 1 ^C] -phenylalanine'' 0.06/zmol/kg-min 490 //moi 
[2,3,3-^H]-phenylalanine® 2 mCi bolus 2 mCi, 36.5 mmol° 
®ICN Radiochemicals, Irvine, CA. 
''Tracer Technologies, Somerville, MA. 
'^ Flooding dose of unlabelled phenylalanine, Sigma, St. Louis, MO. 
The 210 min piasma sampie was tal<en just prior to tlie flooding phe dose. The phe 
flooding dose was prepared by dissolving 36.5 mmol uniabeiied phe in 180 mi distilled water, and 
adding 2 mCi ^H-phe. The solution was warmed to achieve complete solubility, cooled to 
approximately 4(f C, and then rapidly injected into the jugular vein via the infusion catheter. Lambs 
were killed by lethal injection of T-61 (DVM Supply, Spencer, I A) exactly 30 minutes after phe 
flooding dose. Approximately 5g samples of longissimus and gastrocnemius muscles as well as 
liver were immediately dissected and frozen in liquid nitrogen for later analysis. 
Plasma amino acid specific activity 
Plasma leucine specific activity was determined by HPLC and liquid scintillation counting 
by the method of Nissen et. al. (17). Phenylalanine (phe) was isolated from plasma similar to 
leucine (17). Phe, however, was analyzed directly as free amino acid because oxidation of phe to 
a -ketophenylpyruvate results in loss of tracer from phe. Plasma amino acids were isolated using 
a small cation exchange column. The eluent from cation columns was dried and dissolved in a 
small volume of neutral phosphate buffer. Phe was isolated on a C-18 reversed phase analytical 
column (IBM Instruments, Inc.) using an isocratic gradient of 7.7% acetonitrile in 0.1 M phosphate 
buffer. Phe elution was monitored at 254 nm using a variable wavelength detector (Perkin Elmer 
LC75). The phe peak had a retention time of 6.3 min and was quantitated using computer 
integration. Radioactivity in the collected phe peak eluent was determined by liquid scintillation 
counting. Phe specific activity declined linearly from 220 to 240 min (data not shown). Thus, a line 
relating phe specific activity to time was fit by linear regression using time 220, 230, and 240 min 
samples for each lamb. The mean phe specific activity for the flooding dose period (210 to 240 
min) was then calculated as the specific activity of plasma at 225 min for each lamb. 
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Protein bound leu and phe in muscle and liver 
Tissue (~5 g) was suspended in iiquid nitrogen and freeze ground to a fine powder using 
a Waring blender. Samples of freeze-ground tissue (2 g) were subsequently homogenized using 
a Polytron homogenizer in 5 ml deionized water and proteins were precipitated by adding 5 ml of 
3.0N perchloric acid (Fischer). Proteins were pelleted by centrifugation (1900 X g) for 10 min, the 
supernatant was discarded, and the protein pellet rinsed by 2 successive washings in 6 ml of 0.5N 
perchloric acid. Proteins again were collected in a pellet after centrifugation at 480 X g for 10 min. 
Proteins were hydrolyzed according to previously described methods (21) in 15 ml of 6.0N HCI at 
HOC for 6 hours. Amino acids from hydrolysis were isolated by cation exchange chromatography 
as described for plasma. The eluate from cation columns was split between the leu and phe 
specific activity assays (half for each). Leucine was converted to KIC by incubation with amino acid 
oxidase (1.0 mg/ml in 0.5M Tris buffer pH 7.8) for 4 hours. KIC was isolated from the oxidation 
mixture by extraction with methylene chloride as outlined above for plasma. Keto acids were 
resolved on a Dynamax C-18 reversed phase prep column (21.4 mm X 25 cm, Rainin Instruments, 
Emeryville, CA) using an isocratic buffer of 10% acetonitrile in 0.02M phosphate buffer pH 7.0. KIC 
exhibited a retention time of 8.3 min at a flow rate of 14 ml/min. Peal<s were detected using a 
variable wavelength detector (Perldn Elmer) at 214 nm, and quantitated by computer integration. 
The/imol of KIC In each peak was calculated by comparison to peaks resulting from KiC standards 
of similar concentration. Radioactivity of the collected KIC peak was determined by liquid 
scintillation counting. Phe was analyzed without conversion to its keto acid. Eluate from the cation 
columns was dried under a gentle stream of nitrogen gas at 60C. The residue was dissolved in 340 
/il of 0.1 M phosphate buffer pH 7.0 and transferred to a microfuge tube. Insoluble particulate 
matter was pelleted by microcentrifugatlon for 2 minutes. Phe was chromatographed under the 
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same conditions using the same buffer as leu as described above only with detection at 254 nm. 
Phe retention time was approximately 7.4 min. The /zmoi of phe in each peak was determined by 
comparison to standards chromatographed under the same conditions. Radioactivity of each peak 
was determined by scintillation counting of collected eluate. 
Measurement of stable isotope enrichment in plasma 
Isotopic enrichment of leucine and phenylalanine samples were determined by gas 
chromatography-mass spectrometry on a Hewlett Packard GCMS system (5890/5970). A 25m X 
0.2mm crosslinked methylsilicone capillary column (0.11 um film thickness) with a column flow rate 
for 1 ml/min was used. Temperature ramps of 50-20(f C at 4(f C/min (held at 20(f C for 0.8 min) 
and 200-300° C at 60° C/min were used. Leucine and phenylalanine peaks were quantitated in the 
same run. Leucine eluted at 6.3 minutes while phenylalanine eluted at 8.6 minutes depending on 
actual column length and age. Using the MTBSTFA derivative (Regis Chemical, Morton Grove, IL), 
the major base ions (M) of leucine and phenylalanine were monitored at m/z = 302. Dg-leu was 
monitored at m/z = 305; ^^C-phe was monitored at m/z = 303. A major ion fragment of natural 
3MH was monitored at m/z = 238. Peaks for each ion were quantitated using computer integration 
(Hewlett Packard Chemstation) based on peak height. Isotopic enrichment in M + 1 (^^C), and M+3 
(O3) were corrected for natural background enrichment by subtracting M+1 and M+3 enrichments 
observed in time 0 samples which were collected prior to isotope infusion. 
Calculations 
Plasma leucine and phenylalanine flux were calculated from the formula 
F = l/Sp Equation 2 
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where F is the flux ^mol/kg-min), I is the infusion rate (f/mol/kg-min or dpm/kg-min) and Sp is 
the enrichment (atoms percent excess) or specific activity (dpm///mol) of the tracer in piasma at 
plateau. 
Protein synthesis in tissues based on constant infusion of ^H-leu were calculated as 
described previously (8) from the formula 
S| Kj-Kg KpKj Equation 3 
where S,, is specific activity of leucine bound in tissue protein, S, is specific activity of leucine in 
intracellular fluid, K, is the rate constant for rise in specific activity of intracellular leucine, and K, is 
the fractional synthesis rate (FSR). For muscle, RK^ was used as an approximation for K, where 
R is the ratio of protein-bound leucine to intracellular leucine in muscle (8). R was taken to be 550 
based on previous work (6,26). For liver, K. is nearly equal to or the rate constant for rise in 
specific activity in plasma. Because FSR is relatively insensitive to the actual value of K^, and 
because should be relatively constant across lambs, was estimated as 80 day'^  from the 
shape of the plasma enrichment curve. The absolute rate of protein synthesis (ASR) in g/day was 
calculated as 
ASR = (FSR) P Equation 4 
where P is the estimated grams of protein in the whole organ. P was estimated by assuming 20% 
of whole organ weight was protein. 
Protein synthesis based on the phe flooding dose method was calculated according to 
previously reported equations (1,7). 
Sfa/Sj = Kgt Equation 5 
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where t is the time of flooding dose. S| was taken as the average specific activity of phe in plasma 
over the flooding dose period. 
Fractional breakdown rate (FBR) was calculated using the 3-methylhistidine production rate 
(PR,/imol/day) as estimated by the kinetic compartmental model and total muscle 3-methylhistidine 
content (C, //mol) by the formula; 
FBR = PR/C Equation 6 
C was estimated by determining the 3-methylhistidine content in longissimus muscle and 
extrapolating to total muscle 3-methyihistidine by assuming 33% of live body weight to be muscle. 
Statistics 
Correlation and multiple regression analysis were determined using the Corr and Stepwise 
procedures of SAS, respectively (SAS Institute Inc., Gary, NC). In multiple regression, variables 
were added such that R^ was maximized. The best combination of parameters to predict muscle 
mass was evaluated based on the highest R^ obtained by multiple regression while maintaining a 
significance level of p<0.05. 
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RESULTS 
General parameters measured 
The mean and coefficient of variation (CV) for each protein variable is shown in Table 3. 
Nitrogen balance was used as a metabolic indicator of whole-body protein status and was positive 
during the 10-day period of measurement. Growth during this period in metabolism crates, 
however, was likely less than maximal. Creatinine excretion during the last 5-days of this period 
was used as a metabolic indicator of muscle mass and was less variable than nitrogen balance (CV 
= 28%, 44%, respectively). Live weight and carcass weight were very similar among all lambs (CV 
= 4%) while more variation was evident in muscle weights and liver weights among lambs (CV = 
9-14%). The combined weight of the longissimus, gastrocnemius, and psoas was used as an 
indicator of total muscle mass (CV = 8%). 
Several isotope tracer models were used to measure tissue protein synthesis and protein 
breakdown as well as plasma amino acid flux (Table 3). The specific activity (SA) and enrichment 
of leu and phe from respective tracers in plasma were used to calculate fractional synthesis rate 
(FSR) of tissue proteins (^H-leu and ^H-phe tracers) as well as plasma amino acid flux (^H-leu, Dg-
leu, and ^^C-phe tracers). With respect to the tracers, leu SA was more variable (CV = 17%) 
than phe SA (CV = 9%). This may have been due in part to the 10-fold lower activity of leu 
samples and accuracy associated with liquid scintillation counting. 
Both leu flux rates (Dg and tracers) were correlated (r = 0.40, p < 0.05). Phe flux based 
on the ^^C-phe tracer was 15% of ^H-leu flux, and 27% of Dg-leu flux. It was correlated to ^HWeu 
flux (R = .41, p<.05) but unrelated to Dg-leu flux (R = .23, p>.1). Phe flux in lambs has not been 
previously reported. 
Table 3. Means and standard deviations of variables measured 
Variable n= Mean CV* 
Nitrogen Intake (g/d)® 36 35.4 15.3 
Nitrogen Balance (g/d)® 35 7.9 44.2 
Creatinine excretion (mg/day)*^ 36 594 28.1 
Live weight on day 16 (kg) 36 30.2 4.3 
Carcass weight day 16 (kg)® 35 14.4 4.3 
Longlssimus Dorsi weight (g)' 36 368 9.2 
Gastrocnemius weight (g)' 36 107 9.8 
Psoas Major weight (g)' 36 66.4 13.5 
Liver weight (g)* 35 774 12.9 
Total 3-muscle weight (g)® 36 542 8.3 
Plasma ^H-leu specific activity (dpm/nmol)^ 30 8.84 16.6 
Plasma ®H-phe specific activity (dpm/nmol)' 30 84.7 9.5 
Plasma Dg-leu enrichment (%)' 35 1.19 52.8 
Plasma ^^C-phe enrichment (%)' 35 4.30 34.6 
Leucine Flux ^H-leu Oumol/kg-min)*' 30 12.1 22.6 
Leucine Flux Dyleu ^mol/kg-min)*^ 35 6.7 38.1 
Phenylalanine flux ^^C-phe (umol/kg-min)** 35 1.8 34.9 
Longissimus bound ^H-leu SA (dpm/umol)' 30 29.3 26.2 
Longlssimus bound ^H-phe SA (dpm/umol)' 30 161 28.2 
Gastrocnemius bound ^H-leu SA (dpm/umol)' 30 44.3 21.0 
Gastrocnemius bound ^H-phe SA (dpm/umol)' 30 107 24.0 
Liver bound ^H-leu SA (dpm/umol)' 30 456 22.2 
Liver bound ^H-phe SA (dpm/umol)' 30 500 15.9 
Longissimus FSR leu (%/d)'" 30 3.0 29.0 
Longissimus FSR phe (%/d)'^  30 9.1 28.4 
Gastrocnemius FSR leu (%/d)'" 30 4.2 24.5 
Gastrocnemius FSR phe (%/d)'^  30 6.1 27.5 
Liver FSR leu (%/d)'" 30 36.2 27.3 
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Variable n= Mean cv" 
Liver FSR phe (%/d)'" 30 28.7 18.9 
3MH production rate Oumol/day)" 36 301 29.6 
Fractional breakdown rate (%/day)" 36 5.2 29.5 
3MH Pool 3 (umol)" 36 495 46.6 
Longissimus NPA leu (%/day)° 30 -2.2 -80.6 
Longissimus NPA phe (%/day)° 30 4.0 78.6 
Gastrocnemius NPA leu (%/day)° 30 -1.0 -159.0 
Gastrocnemius NPA phe (%/day)° 30 0.9 179.0 
^Number of lambs Included in each measurement. 36 lambs were studied overall, but only 
30 were included in the radioisotope models (protein synthesis). Because one lamb died on the 
morning of stable isotope infusions, it is included In all measures except plasma flux and tissue 
protein synthesis. 
^Coefficient of variation (CV) for each variable. 
'^ Nitrogen intake and nitrogen balance were determined during the last 10 days of a 15 day 
period of study. Nitrogen content of feed, urine and feces were determined by the Kjeldahl 
procedure. 
^Creatinine excretion was determined In urine collected during the last 5 days of the 10 day 
nitrogen balance period. 
^Lambs were slaughtered after constant infusion and flooding dose protein synthesis 
measurements. Carcass weight reflects body weight minus head, hide, viscera, and feet. 
^Individual muscles on the left side of the carcass were dissected and weighed. 
Longissimus and gastrocnemius muscles on the right side were sampled for protein synthesis 
measurements. Total liver weight was also determined. 
®Total muscle weight was determined as the sum of longissimus, gastrocnemius and psoas 
muscle weights. This parameter was used as the indicator for total body muscle. 
^Plasma leucine (leu) specific activity SA as used for precursor SA in calculations of protein 
fractional synthesis rate (FSR) and in determination of plasma leu flux. SA was calculated as the 
average SA of leucine and its ketoacid a -ketoisocaproic acid at plateau during a 240 minute primed 
dose constant Infusion of ^H-leu. Plateau SA was reached by 60 minutes. 
'plasma phenylalanine (phe) SA was assessed after a flooding dose of phe (2.0 mCi, 36.4 
mmol unlabelled phe). Plasma phe SA decreased linearly over the 30 minute period (time 210-240 
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Table 3. (continued) 
min of constant infusion). The average SA over this period was calculated by linear regression of 
SA measured at 220, 230, and 240 minutes for each lamb. The calculated value for 225 mln was 
used as average precursor phe SA in calculating FSR. 
^Atoms percent excess of Dyleu or ^^C-phe relative to natural leu or phe in plasma at 
plateau after a 4-hour primed constant infusion of ^H-leu or ^^C-phe. 
"^Plasma amino acid flux was determined by constant infusion of ^H-leu, Dg leu, and ^^C-
phe. Flux was calculated as outlined in the text. 
'Leu and phe SA bound in tissue protein at the end of infusion. At time 240 min of constant 
infusion (30 min following phe flooding dose), lambs were sacrificed. Tissues were immediately 
sampled and frozen for later determination of leu and phe SA bound in tissue protein. 
^FSR is fractional synthesis rate as determined by the ^H-leu constant infusion method (leu 
model) and phe flooding dose method (phe model). See text for equations. 
"3-methylhistidine (3MH) kinetics were estimated by bolus injection of Dg-3-methylhistidine 
followed by serial sampling of plasma and urine. 3MH production rate and fractional breakdown 
rate (FBR) of myofibrillar protein were determined by compartmental analysis using a 3-pool model. 
The amount of 3MH in pool 3 was related to muscle size. 
°Net protein accretion rate (NPA) was estimated as the difference between FSR (synthesis) 
and FBR (breakdown) for each muscle. FSR was determined in individual muscle while FBR was 
an estimate for muscle tissue as a whole. 
The FSR was 3-fold higher for the phe model than for the leu model in the longissimus 
muscle, and 45% higher in the gastrocnemius muscle. Estimates of liver FSR were similar between 
models. In addition to protein synthesis, estimates of protein breakdown were also obtained (Table 
3). The fractional breal<down rate FBR of myofibrillar protein was calculated from the production 
rate of 3-methylhistidine (see materials and methods). The production rate of 3-methylhistidine 
refers to the net input of free 3-methylhistidine into the system from muscle protein degradation. 
The production rate can be extrapolated to overall fractional protein breakdown by estimating the 
total amount of 3-methylhistidine bound In muscle protein. FBR as estimated by the 3-
methylhistidine model was comparable to the FSR's of longissimus and gastrocnemius muscles 
(approximately 5-10%). 
Net protein accretion (NPA) was estimated for each muscle using the FSR from either the 
leu constant infusion model or the phe flooding dose model along with the FBR as estimated by 
plasma 3MH kinetics. NPA was negative in both the longissimus and gastrocnemius muscles as 
based on the leu model FSR, but was positive for both muscles when based on the phe model FSR. 
This is due to the fact that phe FSR was higher than leu FSR. 
Correlation analysis and coordinated tissue growth 
To better evaluate the concept of the ability of each model to detect relative differences, 
the overall data set was evaluated by correlation analysis. The underlying assumption in this 
analysis was that growth of tissues was coordinated within an animal and that the leu constant 
infusion model and phe flooding dose model should give similar estimates of synthetic rates 
between tissues and within tissues. The idea of coordinated growth among like tissues is supported 
by the correlation of tissue weights outlined in Table 4. Longissimus dorsi, gastrocnemius, and 
Table 4. Correlation of tissue weights^ 
Correlation (R)^ Gastrocnemius Psoas Heart Liver 
Longissimus 0.670*** 0.370* -0.074 -0.224 
Gastrocnemius 0.580*** -0.362* -0.098 
Psoas -0.329* -0.052 
Heart 0.358* 
* P < 0.05, ** P < 0.01, *** P < 0.005 
^Individual muscles were dissected from the left side of the carcass following isotope 
studies. Organ weights were corrected for sample taken for protein synthesis. 
h'he R values are denoted for comparisons among tissues by matching rows and columns. 
psoas major muscle weights were significantly correlated (R>0.37, P<.05). Thus, a lamb with a 
large longissimus muscle also had a large gastrocnemius and psoas muscle. Skeletal muscle 
weight was uncorrelated to liver weight. Moderate negative correlations were observed between 
gastrocnemius and heart (r= -0.36, p=0.03) as well as psoas and heart (r= -0.33, p=0.05). Liver 
and heart weight were also moderately correlated (r=0.36, p=0.03). Thus, it appears that the idea 
of coordinated growth, especially among indivkJual muscles, is a valid basis for comparison of 
protein synthesis models. 
The idea of coordinated protein synthesis among individual muscles was used to evaluate 
the leu constant infusion and phe flooding dose models. For example, a high fractional synthesis 
rate (FSR) in the longissimus muscle should be correlated to a high FSR in the gastrocnemius. 
Such would be the requirement for coordinated growth among skeletal muscles. Table 5 shows 
the correlations between FSR's for each organ measured. The FSR's based on the leu model were 
highly correlated (P<.005) between the longissimus and gastrocnemius muscles (R = .64), 
between the longissimus and liver (R = .54), and between the gastrocnemius and liver (R = .57). 
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Table 5. Correlation of fractional synthesis rates among tissues and models 
FSR correlations (R) Leu Model^  Phe Model'' 
Longissimus vs Gastrocnemius^ 0.638*** -0.256 
Longissimus vs Liver 0.544*** -0.146 
Gastrocnemius vs Liver 0.571*** 0.387* 
Leu vs Phe (Longissimus)'^ -0.133 
Leu vs Phe (Gastrocnemius) 0.145 
Leu vs Phe (Liver) 0.227 
ASR correlations (R) 
Longissimus vs Gastrocnemius 0.682*** 0.106 
Longissimus vs Liver 0.483** -0.188 
Gastrocnemius vs Liver 0.525*** 0.187 
Leu vs Phe (Longissimus) 0.034 
Leu vs Phe (Gastrocnemius) 0.271 
Leu vs Phe (Liver) 0.461** 
* P < 0.05, ** P < 0.01, *** P < 0.005 
^Fractional and absolute synthesis rates used in correlations were based on the leucine 
constant infusion model. 
^Fractional and absolute synthesis rates were based on the phenylalanine flooding dose 
model. 
"Correlation between FSR measured in the longissimus vs FSR measured in the 
gastrocnemius with both FSR's based on the same model. 
"^Correlation between FSR based on the leu model vs FSR based on the phe model with 
both FSR's estimated in the longissimus. 
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The FSR's based on the phe flooding dose model were only correlated between the gastrocnemius 
and liver. Correlations among absolute synthesis rates (ASR's) were similar to the FSR's. ASR's 
were correlated between tissues using the leu model, but not the phe model. 
The correlations between models within each tissue are also shown In Table 5. No 
significant correlations were observed for FSR between models in any tissue considered. For 
example, a high FSR for longisslmus muscle measured by the leu constant infusion method was 
uncorrelated to a high FSR as measured by the phe flooding dose model. Leu and phe ASR's were 
also uncorrelated within individual muscles, but were correlated within the liver (R=.46, P<.01). 
Use of single variables to predict total muscle mass 
The combined weight of the longissimus, gastrocnemius, and psoas muscles were used 
as an indicator of total muscle mass. The correlation of each individual variable to total muscle 
mass is shown in Table 6. Creatinine excretion, phenylalanine flux, and 3MH pool 3 were 
significantly correlated to total muscle weight (P<.05). All other variables, when considered 
individually, were unrelated to total muscle weight. The relationship between each of the significant 
individual variables and total muscle weight is illustrated graphically in Figure 2. Creatinine excretion 
and 3MH pool 3 were positively correlated to total muscle mass while phe flux was negatively 
correlated to total muscle. 
Multiple variable prediction of total muscle mass 
Multiple regression models were constructed based on one of the significant single base 
variables (creatinine excretion, phe flux, or 3MH pool 3) and the remaining non-significant variables 
outlined in Table 6. The best 1,2,3, and 4 variable models with the highest correlation to total 
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Table 6. Simple correlations and single variable regression for predicting total muscle weight 
Variable^ n 
Simple 
Correlation'' 
Regression 
Coefficient" Intercept 
Creatinine excretion 36 0.42* 0.1435 457.11 
Phenylalanine flux ^^C-phe 35 -0.39* -35.84 601.89 
3MH Pool 3 36 0.33* 0.0884 498.57 
Gastrocnemius FSR phe 30 0.26 914.39 477.33 
Gastrocnemius FSR leu 30 0.22 1092.96 487.63 
Gastrocnemius NPA phe 30 0.20 588.03 527.61 
Live weight 36 0.16 7.59 313.23 
Liver FSR phe 30 0.13 145.87 491.21 
Gastrocnemius NPA leu 30 0.13 491.35 538.01 
Nitrogen balance 36 0.10 1.47 531.01 
Leucine flux ^H-leu 30 -0.06 -1.09 546.24 
3MH production rate 36 0.05 0.0359 531.33 
Longissimus NPA phe 30 -0.05 -111.09 537.44 
Fractional breakdown rate 36 0.04 178.52 533.08 
Longissimus FSR phe 30 -0.03 -89.33 541.20 
Liver FSR leu 30 -0.02 -9.63 536.52 
Leucine flux D^-ieu 35 0.02 0.394 535.77 
Longissimus FSR leu 30 0.02 112.42 529.69 
Longissimus NPA leu 30 -0.02 -89.15 531.07 
Nitrogen intake 36 0.00 0.05 527.42 
* P < 0.05 
'See Table 3 for parameters definitions. Regression coefficients for FSR (fractional 
synthesis rate) and NPA (net protein accretion) parameters are for data expressed as fraction per 
day rather than percent per day. 
^Simple correlation of the individual parameter to the sum total weight of the longissimus 
dorsi, gastrocnemius, and psoas major muscles which were dissected following infusion studies. 
^Regression coefficient and intercept for each single parameter vs total muscle weight. 
Figure 2. Best singie variable correlations to total muscle weigiit. See Table 6 for regression 
coefficients. Total muscle was calculated as the sum of longissimus dorsi, 
gastrocnemius, and psoas major muscle weights and used as an indicator of total 
carcass muscle. A) Creatinine excretion vs total muscle weight. Creatinine excretion 
was determined during the 5-days prior to the end of the study. 6) Correlation of 
phenylalanine flux to total muscle weight. Phenylalanine flux was determined by 
constant infusion of ^^C-phenylalanine during the last day of study. C) Correlation of 
3-methylhistidine pool 3 to total muscle weight. 3-methylhistidine kinetics were 
assessed by compartmental analysis during the last 5 days of study. **P<.05. 
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muscle weight are shown in Table 7. In each case, addition of selected variables to the base 
variable resulted in a better predictive estimate of muscle weight as evidenced by a higher R value. 
FSR in the gastrocnemius muscle and the liver based on the phe flooding dose model, as well as 
plasma leu flux based on ^H-leu infusion were included In the phe flux and creatinine models in 
preference to all of the other variables considered. Gastrocnemius FSR based on the leu and phe 
models along with plasma leu flux based on Dyleu infusion were included in the 3MH pool 3 
models. On the whole, of the variables considered in Table 6, it appears that liver and 
gastrocnemius FSR as well as leu flux have the most predictive value in multiple regression models. 
In fact, these variables, when combined with phe flux (Phe flux models. Table 7), have more 
predictive value than combining phe flux, 3MH pool 3, and creatinine (Combined single models. 
Table 7). Therefore, it appears that a multiple variable approach to describing muscle mass is 
better than any single variable alone. 
in order to determine the best multiple variable model to describe total muscle mass, ail 
variables from Table 6 were included In multiple regression analysis. The best 1,2,3, and 4 
variable models with the highest R values were identical to the models based on phe flux in Table 
7. Using up to 3 variables in the model improved the correlation of the model to muscle weight: 
R = .43 (P<.05) for the 1 variable model; R = .62 (P<.01) for the 2-variable model; and R = .71 
(P<.001) for the 3-variable model. Further addition of up to seven variables resulted in only small 
improvements in correlation to total muscle weight. The maximum correlation obtained was R=.80 
(P<.001) for 7 to 10 variables. Thus, it appears that the simplest multiple regression model to 
describe total muscle weight was a 3-varlable model including plasma phenylalanine flux along with 
liver and gastrocnemius FSR based on the phe flooding dose technique. 
Table 7. Multiple regression models to predict total muscle weight based on the 3 single 
variables that were correlated to muscle weight^ 
Parameters and Coefficeints'' 
Model base° 1 2 3 4 Intercept Rd 
Phe Flux 
Models Phe flux 
Liver 
FSR phe 
Gastrocnemius 
FSR phe 
Leu flux 
^H-leu 
1 variable -38.96 602.00 .43** 
2 variables -68.06 635.24 471.40 .62*** 
3 variables -74.46 516.43 1293.2 438.01 .71*** 
4 variables -83.44 482.29 1500.0 4.512 396.51 .74*** 
Creatinine 
Models Creatinine 
Gastrocnemius 
FSR phe 
Liver 
FSR phe 
Leu flux 
^H-ieu 
1 variable 0.1356 457.20 .39** 
2 variables 0.1478 1081.8 384.47 .50** 
3 variables 0.1582 902.4 162.94 342.82 .52** 
4 variables 0.1730 783.5 246.75 -3.513 360.28 .54* 
^Multiple regression models were calculated using the Stepwise procedure of SAS. Multiple 
variable models were based one of the significant base variables (creatinine, phe flux, or 3MH pool 
3) plus all non-significant variables listed in Table 6 . The progression of improvement in with 
1,2,3, and 4 variable models show that multiple variable models give a better prediction of total 
muscle even though variables added to the base variable were not significantly related to total 
muscle mass when considered alone. 
^he variables included in the best 1, 2, 3, and 4 variable models along with the regression 
coefficients are shown for each model base. See Table 3 for parameter definitions. Single variable 
regression coefficients may differ from those reported In Table 3 because only 30 lambs common 
to all variables were used in this in multiple regression analysis. 
"The model base was one of the 3 single variables that was significantly correlated to total 
muscle weight in Table 6. 
'^ Simple correlation of multiple variable model to total muscle weight. 
°3-methythistidine pool 3 as estimated by 3-pool compartmental model (see text for details). 
'Multiple regression models considering only phe flux, creatinine, and 3MH pool 3 variables 
without including other variables. 
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Table 7. (continued) 
Parameters and Coefficeints'' 
Model base*^ 1 2 3 4 Intercept Rd 
3MH Pool 3® 3MH Pool 3 
Gastrocnemius 
FSR phe 
Leu flux 
D,-leu 
Gastrocnemius 
FSR leu 
1 variable 0.1022 482.33 .35** 
2 variables 0.0945 790.71 437.72 .42* 
3 variables 0.0962 895.16 -5.131 463.27 .46* 
4 variables 0.0972 804.05 -7.477 1387.69 425.55 .48* 
Combined 
Single Models^ Phe flux 3MH Pool 3 Creatinine 
1 variable -38.96 602.00 .43** 
2 variables -37.67 0.0971 551.51 .54*** 
3 variables -28.99 0.0912 0.0720 498.82 .57*** 
*P<0.1, **P<0.05, ***P<0.01 
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DISCUSSION 
Methodological differences in the current study 
Several differences were observed between isotope models which were designed to 
measure the same metabolic process. Plasma amino acid flux was calculated from plasma SA and 
enrichment of radio and stable isotope tracers, respectively. Leucine flux, as estimated by the ^H-
leu tracer, was 44% higher than leu flux estimated by the Dg-leu tracer. The reason for this is not 
entirely clear. Absolute flux rates reported here are also much higher than previously reported (10). 
However, the lambs in previous studies were measured In the fasted state while the current study 
was conducted in the fed state. Leu absorption from the gut during the fed state might account 
for the higher values for leu flux in this study relative to previous work. In general leu flux based 
on the Dg-leu tracer appeared to be more reasonable than flux based on the ^H-leu tracer in 
relation to previous work. 
Differences were also evident among protein synthesis models in that the FSR estimated 
by flooding dose model was 45 to 300% higher than the constant infusion model in muscle. 
Typically, FSR's based on the flooding dose method (1,7,12,22) have been numerically higher than 
FSR's estimated by constant infusion (2,5,23). Yet, the two methods have never been compared 
directly. In practice, however, the absolute values for FSR may be less important than the ability 
of these models to detect relative differences in protein synthesis. 
Advantages and disadvantages of large dose and constant infusion techniques 
The first objective of the current study was to directly compare the constant infusion and 
flooding dose techniques for measuring protein synthesis in liver and muscle. The assumptions 
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and mathematical approach to each method have been described previously (7,26). In prior 
investigations, these techniques have been used independently to study changes in tissue protein 
synthesis which result from changes in diet, age, endocrine status, or other parameters (1 -3,23,25). 
Some theoretical advantages and disadvantages seem apparent from the development of 
these models. The large dose flooding technique was developed to resolve the problems 
associated with defining the specific activity of the precursor pool which is used to calculate protein 
synthesis. In this technique, a large dose of radioactive tracer is administered along with a flooding 
dose of unlabelled tracer such that metabolic body pools of the amino acid are "flooded." The 
intracellular pool of that amino acid is expanded greatly from the excess in plasma such that 
specific activity rapidly increases to a value approximating that of plasma. Thus, the advantages 
of this technique include an improved estimate of intracellular specific activity, minimal recycling 
of tracer from protein over the short period of study, and simplicity in calculations. The 
disadvantages of this method are the large amount of tracer needed, the requirement for very 
accurate timing of tissue sampling, and problems with the large unphysiological dose of tracer 
amino acid. This dose may alter metabolism and consequently the rate of protein synthesis. 
The other common method to measure protein synthesis is the constant infusion method. 
The advantages of this method over the flooding dose technique are that smaller amounts of tracer 
are required, timing of samples is not as critical, the dose of tracer is more physiological, and 
plasma amino acid flux can be measured at the same time. The disadvantages are that the 
mathematical approach is complex, the definition of an appropriate precursor specific activity for 
use in calculations is difficult, and potential recycling of tracer over the period of study may bias 
results (26). 
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Model comparisons based on correlation analysis 
The present study is the first to outiine the simultaneous comparison of these models in 
several tissues of lambs. Such a comparison is valuable considering the possible advantages and 
limitations of the large dose and constant infusion techniques in measuring relative rates of protein 
synthesis in skeletal muscle and liver. The models were first evaluated on the basis of coordinated 
tissue growth under the assumption that protein synthesis in one muscle should be related to 
protein synthesis in another muscle if coordinated tissue growth and protein accretion were 
occurring. Moreover, the rate of protein synthesis as assessed by the two methodologies should 
also be correlated if the methods are measuring the same protein synthesis rates. 
As seen in Table 5, the FSR's between individual muscles and the liver were correlated 
when assessed by the leu constant infusion method, but uncorreiated when assessed by the phe 
flooding dose method. For example, a high FSR in the longissimus was related to a high FSR in 
the gastrocnemius when measured by the leu method but uncorreiated when measured by the phe 
method. In addition, the leu FSR and phe FSR within a muscle or liver were uncorreiated. Thus, 
the FSR measured by the leu method was not related to the FSR as measured by the phe method. 
The reason for a lack of correlation among tissues and models is not clear. One plausible 
reason may the difference in the amount of tracer recycling In each method which could effect the 
relative amount of short and long half-life proteins containing labelled amino ackJ tracer. For 
example, the phe model may primarily label short half-life proteins such as enzymes and regulatory 
proteins during the short incorporation time of 30 minutes. Little recycling of tracer from labeled 
protein back into the free amino acid pool occurs because of the short labelling period. In addition, 
recycling has a relatively small effect on precursor SA because the precursor pools of phe are 
"flooded" with large amounts of phe. The net result of minimizing tracer recycling with the phe 
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model Is that the phe model may more closely reflect the synthesis of enzymes and regulatory 
proteins than the leu model. Knowing the possible metabolic differences between the 
gastrocnemius (primarily fast-twitch fibers) and the longissimus (primarily slow twitch fibers) as well 
as differences between muscle tissue and liver tissue, it seems reasonable that the synthesis of 
these short half-life proteins in different muscle types and different tissues be uncorrelated. 
The synthesis rate of long half-life proteins such as the myofibrillar proteins and other 
structural proteins in the cell, on the other hand, should be correlated between different muscles 
and organs because accumulation of these proteins Is related to tissue size. The synthesis rate of 
these proteins may be more accurately measured by the leu model due to the longer period of 
incorporation. While tracer recycling may be a factor in accurately measuring the synthesis rate 
of short half-life proteins in this case, the period of study Is still sufficiently short (4-hours) to have 
little effect on long half-life structural proteins. Thus, if recycling exists, the synthesis rate of the 
entire protein population may be underestimated by the constant infusion model. The net result, 
however, is that the label incorporation into structural proteins may be better represented by the 
leu model than the phe model. If this is true, the FSR measured by the leu model should be 
correlated between different muscle types. On the whole, the differences in correlation analysis 
between the models might be explained on the basis of the differing protein populations within the 
tissue which may be labeled at different rates depending on the methodology used. 
Model comparisons based on ability to predict muscle weight 
In addition to correlation analysis, another basis for evaluating these two models is their 
relative ability to predict total muscle weight. As seen In Table 6, no significant correlations between 
FSR and muscle weight were observed for either model. In considering individual tissue FSR's, 
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however, the phe model exhibited a higher correlation between FSR and total muscle weight than 
the leu model in the longissimus, gastrocnemius, and liver. This indicates that the phe model may 
more closely reflect muscle weight. As a result, phe-based FSR's were preferentially Included into 
multiple variable models because they exhibited a greater improvement in the than leu-based 
FSR's (Table 7). This suggests that the phe model may be more useful in predicting total muscle 
weight when Included with other variables which estimate protein status such as plasma phe flux, 
nitrogen balance, and urinary creatinine excretion. 
The net result of this direct comparison of the leu constant infusion and phe flooding dose 
techniques to measure protein synthesis is to show that the models, contrary to previous thought, 
in fact measure different relative rates of protein synthesis in the same organ. A theoretical reason 
for these methodological differences may lie in the relative amount of tracer In the varied protein 
species within the tissue, but further research Is needed to fully explain the apparent disparity 
between the models. In practice, however, it appears that the phe model may have greater utility' 
in predicting the actual differences in muscle size which may exist. 
Overall assessment of models to measure muscle mass 
The second objective of the present study was to evaluate a variety of models to assess 
protein status and determine which models, alone or in combination, best predict muscle weight. 
Of the models considered In Table 6, three parameters were significantly correlated (P<.05) to 
muscle weight: urinary creatinine excretion (R=.42), plasma phe flux (R=-.39), and 3-methythistidine 
(3MH) pool 3(R = .33). While previously published reports have shown that creatinine excretion may 
be a valid indicator of muscle mass in humans (13) and cattle (24), the present study suggests that 
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plasma phe flux and 3MH pool 3 may also be valid indicators of muscle mass in lambs when 
considered individually. 
More importantly, however, the present study shows the potential utility of using several 
techniques in combination to assess muscle mass. The simplest multiple regression model with a 
high correlation to total muscle weight contained 3 variables and included plasma phe flux, as well 
as liver and gastrocnemius FSR (phe model). More complex models identified by the statistical 
analysis indicated that further addition of leu flux, 3MH pool 3, and longissimus NPA (phe model) 
offered only minimal improvement in the overall correlation of the model to total muscle weight. 
This suggests that the best overall methodology to measure the dynamics of protein metabolism 
in vivo as they relate to muscle growth is to estimate plasma amino acid flux as well as tissue 
protein synthesis. The specific methodologies compared in the present study suggest that phe may 
be a preferred tracer over leu for flux measurements because plasma phe flux is significantly 
correlated to muscle mass (R = -.39, P<.05). 
In conclusion, a direct comparison of constant infusion and large dose flooding techniques 
to measure tissue protein synthesis indicated that distinct differences exist between models in the 
actual FSR's measured and the relationship of FSR's among tissues and organs. Previous 
assumptions that the two methods measure the synthesis of similar protein pools may be invalid 
because synthesis rates based on the 2 methods In the same tissue were uncorrelated. An overall 
assessment of the common methodologies to measure protein status in vivo indicated that the best 
measure of muscle protein accretion is plasma phe flux combined with liver and gastrocnemius FSR 
based on the large dose flooding technique. These findings suggest that a relatively non-invasive 
and simple technique could be developed to predict muscle mass using isotopic methods to 
measure plasma phe flux and tissue FSR. 
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GENERAL DISCUSSION 
P -agonist mechanism of action 
One of the major contributions of the present work was the empKiasis on a multiple method 
approach to understanding whole-body and muscle protein metabolism. It appears that a 
comparative approach looking at multiple metabolic pathways and organs with a diverse variety of 
methods was more informative than using any single technique alone. It also demonstrated that 
results can easily be misinterpreted if the experimental approach is too narrowed and focused. 
The P -agonist paper illustrates the utility in examining multiple pathways. The experimental 
approach centered on describing the mechanism of P-agonist stimulation of muscle protein 
accretion. The general working idea was that protein accretion results from a balance between 
protein synthesis and protein breakdown. Much of the previous work has centered on measuring 
only one of these parameters (protein synthesis). Such a limited approach could have been 
misleading in present work because some muscles exhibited an increase in protein synthesis 
(gastrocnemius) while others showed no change {longissimus) in protein synthesis (FSR) due to 
P -agonist treatment. Results would have been interpreted much differently if this study was limited 
to only determining protein synthesis in single muscle-type. 
Considering protein synthesis without measuring protein breakdown could have also been 
misleading, A trend for an overall decrease in myofibrillar protein breakdown was observed in this 
study due to P -agonist administration in lambs. This is the first paper to experimentally demonstrate 
an effect on protein breakdown in lambs. Previous work has only been able to speculate on the 
effects on protein breakdown as estimated by the difference between protein accretion (growth) and 
protein synthesis. Thus, the present study suggests that p -agonists appear to increase protein 
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synthesis as well as decrease protein breakdown in muscle. In fact, the relative response of each 
muscle may be different depending on muscle type because while the muscle weight increase 
appeared to be similar between muscles (~15%), the increase in protein synthesis was much 
greater for the gastrocnemius than for the longissimus. A limited experimental approach focussing 
on only one technique or muscle type would have overlooked such an effect. 
The advantages of the using a multiple organ approach are evident in the observation that 
the liver may have a influence on the P -agonist response elicited in muscle. Previous work has 
described only minor changes in liver weight due to p -agonist treatment, but effects on liver protein 
synthesis have yet to be reported. While liver weight was unchanged by p -agonist treatment in the 
present study, a decrease in protein synthesis (15% to 30% decrease in absolute synthesis rate) 
was observed in liver. Because the liver contributes greatly to whole-body protein synthesis ("15-
30%), and the liver was able to maintain its protein reserve, this suggests that changes in liver 
protein synthesis may have affected protein metabolism in other organs based simply on nutrient 
availability. For example, it might be reasonable to consider that p -agonists decrease protein 
synthesis in the liver and that muscle growth is stimulated by the increased availability of nutrients 
made available in the post-liver blood supply to the periphery. Thus, p -agonists might exert their 
endocrine action on the liver, and the response of muscle tissue could be a secondary response 
to increased nutrient supply. 
Thus, the multiple method/ multiple organ approach was beneficial in reconciling disparate 
results in the same tissue (skeletal muscle) and in clarifying possible inter-organ relationships which 
may be involved. Such relationships seem obvious when considering the apparent coordination of 
bodily processes, but are often overlooked in experimental settings which tend to narrow the focus 
to a single organ or pathway. The precise mechanism of p -agonist action on muscle growth 
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appears complex. It may Increase protein synthesis in primarily white (glycolytic) fiber type muscles 
like the gastrocnemius while it may decrease protein breakdown in primarily red (oxidative) fiber 
type muscles like the longissimus. More detailed investigations are needed to clarify fiber type 
differences in a variety of muscles and document the apparent changes in protein metabolism which 
may be present. These changes should be parallelled by Increases in mRNA levels (for increased 
protein synthesis) or increases in protease concentration or activity (for decreased protein 
breakdown). 
Evaluation of current methodology 
An appropriate understanding of the advantages and limitations of the methodologies used 
to answer experimental questions is apparent in the present study. This is illustrated In part by the 
second manuscript which focussed on the disparity between constant Infusion and large dose 
flooding techniques to measure protein synthesis. Two of the major criticisms of the constant 
infusion model are tracer recycling and the uncertain estimates of precursor specific activity. Thus, 
the large dose method was developed to flood metabolic pools with a tremendous load of tracer. 
In turn, precursor specific activity over the period of study could be measured more accurately, and 
the effects of tracer recycling could be minimized. Indeed, the flooding dose technique, in its 
approach, appears to offer advantages over the older, more widely used constant Infusion protocol. 
In practice, however, these two methods have never been directly compared. Thus, the real utility 
and practical advantages of one technique over the other have yet to be described. 
By comparing these methods directly in the present study. It appeared that these methods 
measured the synthesis rates of different protein species because the synthesis rates within the 
same muscle were uncorrelated between the methods. A high synthesis rate with one method was 
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uncorrelated to a high synthesis rate with the other method. Thus, it seems that both methods offer 
advantages in different ways. The constant infusion method, for example, may be the method of 
choice in measuring protein synthesis of structural proteins In muscle because estimates of protein 
synthesis were correlated among muscle types and between organs. In other words, a high 
synthesis rate in one muscle corresponded to a high synthesis rate in another muscle. The 
constant infusion method, with a relatively long incorporation period coupled with some tracer 
recycling in short half-life proteins, may favor the labelling of structural proteins. Since these 
structural proteins are an integral part of the tissue mass and growth in individual tissues appears 
to be coordinated, it is reasonable to predict that the synthesis rates of these proteins be correlated 
among muscles and organs. The flooding dose model, however, showed that synthesis rates 
among organs and muscles were uncorrelated. Thus, it may be the method of choice for 
measuring the synthesis of short half-life proteins like enzymes, receptors, and regulatory proteins. 
This may be due to the large dose to minimize recycling and the relatively short time period 
involved (less than 30 minutes). 
At the same time, the flooding dose technique may offer advantages over constant infusion 
when measuring protein synthesis In organs most effected by tracer recycling. Tissues like liver, 
kidney, and the gastrointestinal tract, which exhibit rapid rates of protein turnover, might incorporate 
tracer through protein synthesis and lose tracer through protein breakdown during the period of 
study. Thus, a more accurate rate of protein turnover might be obtained using the flooding dose 
method which minimizes the effects of tracer recycling by using a large flooding dose of tracer and 
a short time period. Such a hypothesis could be tested by further analyzing tissue samples 
collected in this study from highly active organs such as small intestine or kidney. 
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In general, the question of which method is best is difficult to assess. The phe method, 
although it requires large, unphysiological doses of tracer and exact timing, may offer advantages 
over the leu constant infusion method. The phe method was more highly correlated to tissue 
weight and probably measures total protein synthesis more accurately even though the 
measurement of structural protein synthesis may be restricted. In general, while structural proteins 
comprise the majority of tissue mass, the turnover of regulatory proteins, receptor proteins, and 
metabolic enzymes may be the major contributor to overall muscle growth efficiency. Thus, 
accurate measurement of the synthesis of these proteins with the phe method may offer a better 
overall description of muscle growth and animal efficiency. 
Pitfalls and limitations of the current study 
One of the major limitations of such a large study was the requirement that every method 
and metabolic tool be fully functional before it is implemented in such a large number of lambs. 
This was evident in the use of untested ovine pituitary derived growth hormone. This was included 
in the overall experimental design along with the p-agonist as a anabolic regulator of protein 
metabolism. Serious questions arise in the interpretation of the results obtained with growth 
hormone treatments because of the relative uncertainty of the purity and activity of the preparation 
used. If the activity and purity of the preparation used could be documented, the growth hormone 
treatment differences observed may be more meaningful. Admittedly, such faith in commercial 
treatment preparations should be approached with great caution. In light of the fact that NobI 
Laboratories provided partial funding for the completion of the study, however, it seems that the 
limitation imposed by lack of confidence in the growth hormone preparation was offset by the 
economic ability to perform the experiment on this scale at all. 
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Another pitfall was that an insufficient amount of ^^C-KIC (a -ketoisocaproic acid) tracer was 
infused. Thus the ^^C-enrichment in the leucine pool was beyond the limits of detection of the gas 
chromatograph/mass spectrometer. Thus, a comparison of the 2-pool and 1-pool compartmental 
models was not possible with the given data set. Underestimation of the ^^C-KIC infusion rate likely 
resulted from an effort to minimize total costs and not accounting for the slower rate of KIC - leu 
interconversion which may exist in lambs of this size and under these treatment 
conditions. Admittedly, such limitations could not be observed until samples from a few lambs were 
completely analyzed. 
Future directions for further research 
The area of p-agonist influence on muscle growth offers great potential for future 
investigation. Because both protein synthesis and degradation appear to be involved, further 
analysis of the mechanisms involved would be fruitful. For example, specific proteins within muscle 
which may be synthesized at a greater rate could be identified. In fact, this could be determined 
in muscle samples from the existing study by isolating specific proteins and calculating protein 
synthesis by a similar approach. In addition, the mRNA levels for major structural proteins like actin 
and myosin could be measured as an indicator of the synthetic rate of these proteins. 
In the area of protein breakdown, the concentration and activity of key proteases could be 
determined in individual muscles. The cal pains (calcium-activated neutral proteases) have already 
been implicated in mediating the p-agonist-induced decrease in protein breakdown. Other 
proteases may be involved as well. 
The question of regulating muscle protein turnover metabolically by nutrient supply also 
warrants further investigation. The muscle seems to play such a large role in maintaining amino 
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acid supply to organs of higher priority during periods of nutrient deprivation and stress. Thus, it 
seems reasonable that the opposite may also be true. Muscle may serve as a sink for nutrients and 
become overly anabolic provided that all other nutrient requirements are satisfied among the higher 
priority organs. 
Finally, the further development of methodology to measure protein breakdown in vivo could 
have great Impact in understanding protein turnover in the whole-body and selected tissues. 
Preliminary efforts related to this study and others in our lab suggest that compartmental analysis 
of 3-methylhistidine kinetics may offer a unique approach to measuring muscle protein breakdown 
in vivo. In fact, it seems possible that this model could be extended to estimate protein breakdown 
individual muscles. Obviously, further study will be required to validate this approach. 
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